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Abstract 
 
Development and spread of malignant disease are crucially dependent on the 
recruitment and reprogramming of various immune cells. At the primary tumour site, 
tumour-associated macrophages and immature myeloid cells facilitate local invasion 
and neoangiogenesis and promote the establishment of a tumour-permissive 
microenvironment. Systemic cancer spread is preceded by the establishment of a 
permissive microenvironment in the target tissue of metastasis – the premetastatic 
niche.  
As crucial players in the establishment of the premetastatic niche as well as the 
orchestration of tumour immune evasion at primary tumour level, myeloid-derived 
suppressor cells (MDSC) release S100A8/A9, an exosomal protein that contributes to 
metastasis, angiogenesis, and immune suppression. 
S100A8/A9 is a ligand for TLR4 and RAGE and acts as a chemo-attractant to myeloid 
cells. The local S100A8/A9 level is a sensitive indicator of immune cell activity. 
Building on the development of S100A8/A9-specific optical imaging for monitoring of 
local inflammation, I assessed S100A8/A9 imaging for the visualisation of tumour-
associated immune cell activity. I strived to establish local S100A8/A9 imaging signals 
to be coincident with the increased activity of tumour-promoting immune cells and 
therefore indicative of high malignant activity within the primary tumour and the 
establishment of a premetastatic niche in distant tissue. 
A S100A9-targeting antibody has been labelled for optical in vivo imaging and used 
for fluorescence imaging of tumour-associated inflammation in an orthotopic murine 
breast cancer model. The local S100A9-signal could be shown to reflect the tumour-
associated macrophage and MDSC abundance and activity and predict local tumour 
growth. 
To enable systemic imaging of tumour-mediated immune cell activity, the optical 
tracer has been developed into a SPECT tracer for labelling with 111In and tested in a 
well-characterised murine model of local inflammation. 
	   3 
In a syngeneic mouse model of metastatic breast cancer, S100A8/A9-SPECT 
sensitively reflected MDSC abundance and the establishment of an 
immunosuppressive environment in premetastatic lung tissue. A significant correlation 
between the S100A8/A9 imaging signal in the premetastatic lung and the subsequent 
metastatic tumour burden could be established. The results suggest S100A8/A9 as a 
potent imaging biomarker for monocyte activity, reflective of tumour-associated 
immune cell activity. 
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1 Introduction 
Following cardiovascular disease and infections, cancer is still third in the ranking of 
causes of death, accounting for an estimated 8 million deaths per year as recently 
confirmed by the Global Burden of Disease study (1, 2).  
Major progress has been made towards treatment of primary cancer. Surgery and 
endovascular intervention, radiotherapy and chemotherapy greatly evolved over the 
past decades and strongly increased the possibilities of and chances for local tumour 
control.  The majority of cancer-related deaths are, however not caused by the local 
primary tumour growth and local invasion but the development of distant metastasis. 
Therefore, the success of cancer therapy is often determined by the stage and extent 
of disease at the time of diagnosis.  
In breast cancer, the presence of distant metastasis at the time of diagnosis reduces 
the 5-year survival rate by a factor of 4 as compared to those women with localised 
disease – from almost 99% to less than 24% (3). This discrepancy is the raison d’être 
for all screening programs with the aim of early cancer detection. However, it also 
illustrates that oncology does not yet have the sufficient means for effectively treating 
systemic cancer spread – especially the multi-step process of metastasis is still not 
fully understood. Diagnostic approaches only cover some aspects of malignant 
disease, failing to provide vital information on other aspects of cancer (4) including the 
detection of micrometastatic disease and/or the visualisation of tumour- immune cell 
crosstalk. 
Understanding the multi-step process of metastasis with the possibility to identify 
potential for intervention in the development of systemic disease and diagnostic 
approaches for detection and measurement of the early phases of metastasis would 
basically turn cancer from a fatal killer into a local, controllable disease. 
By establishing a first in vivo imaging marker for tumour-mediated immune 
remodelling, this study is intended to provide a versatile method for further research 
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on tumour-mediated, premetastatic tissue priming and offer insights into the process 
of systemic cancer spread. 
2 Background 
2.1 Tumour immunology and immunotherapy 
The innate immune system in vertebrates constantly monitors the body and screens 
for potentially pathological alterations in cells, showing as e.g. variations in cell 
surface markers. Aberrant cells are recognised, labelled and subsequently destroyed 
– a mechanism that enables the control of infection as well as premalignant lesions. 
The presence of certain subtypes of immune cells, CD8+ T cells, Natural killer (NK) 
cells and pro-inflammatory macrophages have been shown to be independent 
positive outcome predictors (5). However, preclinical and clinical data suggest that at 
some point during tumour development, the immune system falls under the influence 
of the tumour and begins to actively support disease development (6). This process is 
called tumour immunoediting. In the context of this escape from immunosurveillance, 
the composition and functionality of tumour-associated immune cells changes and a 
tumour-promoting, immunosuppressive environment is established (7). Only 
successful escape from immunosurveillance and attempted elimination guarantees 
establishment of manifest cancer. 
Beyond changing the immediate environment through local tissue destruction, 
established cancer influences and modulates virtually all physiological systems of the 
body and drives host cells to essentially contribute to malignant development. Host 
cells that are recruited by the tumour support vital steps of tumour development 
beyond the initial lesion establishment. For example, release of pro-angiogenic factors 
like vascular endothelial growth factor (VEGF) activates endothelial cells and results 
in sprouting of new vessels, supplying oxygen and nutrients for the growing tumour 
(8); activation of phagocytes in the immediate tumour environment further supports 
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angiogenesis and enables degradation of extracellular matrix for tumour expansion (9, 
10). 
Although a potential crosslink between malignant disease and the immune system 
has been proposed more than 100 years ago already by Virchow, who observed an 
infiltrate of lymphocytes into solid tumours (11), the potential impact of tumour 
associated immune cells for therapy and the need of appropriate diagnostics has long 
been ignored. Relatively recently, the major role of tumour associated inflammation, 
constituted by tumour educated immune cells, in the process of cancer development 
and spread has been fully recognised (12). In particular, tumour associated 
inflammation, tumour immunosuppression and evasion of anti-tumour immunity have 
been newly called hallmarks of cancer (13). The current effort to establish cancer 
therapy that specifically targets the tumour-associated immune cells rather than the 
tumour cells is a clear indication of this change of paradigm (4).  
Various immune cells accumulate in the primary tumour microenvironment in 
response to active tumour signalling and as secondary effect of the metabolic 
situation in the tumour. The tumour immune infiltrate comprises monocytes and 
macrophages, T cells, mast cells, fibroblasts and dendritic cells. Mature and immature 
variants of all these cells, especially monocytes have been found. The physiological 
anti-tumour immune response, elicited mainly by the tumour expression of aberrant 
surface molecules following proteome mutation, is driven by CD8+ T cells and NK 
cells 
Monocytes and macrophages constitute the biggest group of immune cells in the 
tumour microenvironment and can account for more than 50% of the whole tumour 
mass. Monocytes and macrophages accumulate in response to actively secreted 
specific cytokines, the hypoxic metabolic state in the tumour tissue or necrosis-related 
cell damage associated molecular pattern (DAMP) molecules in the tumour. To 
roughly differentiate the various subtypes of macrophages, functional characteristics 
have been used to define pro-inflammatory macrophages, traditionally activated via 
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the complement immune system (M1) from immunomodulatory macrophages with 
function in tissue regeneration, wound healing and resolution of inflammation, 
activated via alternative pathways (M2) (14). Under physiological circumstances, M1 
and M2 macrophages balance inflammation and tissue growth. In the tumour 
microenvironment, the M2 macrophage dominates over the pro-inflammatory M1 
phenotype. Under the influence of IL-4, IL-13, IL-10 and M-CSF, macrophages 
preferentially lean towards M2 polarisation and support neoangiogenesis via secretion 
of VEGF, supply the tumour with growth factors and also contribute to immune 
remodelling by promoting the accumulation of regulatory T cells (Treg) and myeloid-
derived suppressor cells (MDSC) in the tumour microenvironment. Among other 
functions, monocytes and terminally differentiated macrophages also support local 
invasion and intravasation, representing early steps of distant metastasis: it has been 
shown that immune cells at the active tumour margin establish reciprocal signalling 
loops with tumour cells. Through supply of epidermal growth factor (EGF) to the 
tumour cell and reception of CSF-1 in return, macrophages are virtually guiding the 
tumour cell towards activated vasculature (15). The abundance of tumour-associated 
macrophages (TAM) correlates with outcome and prognosis for selected cancer types 
(16, 17). In preclinical model systems, the depletion of macrophages had a positive 
effect on tumour development (18). 
The physiological balance between effector T cells (CD8+) and Treg (CD4+), required 
to ensure tissue homeostasis and limitation of inflammatory processes is disturbed in 
the tumour environment. While CD8+ effector T cells are the backbone of anti-tumour 
immunity in the context of immunosurveillance, the tumour microenvironment is 
dominated by T cell subtypes that suppress cytotoxic immune activity and inhibit 
recognition of tumour cells as potential targets for immunity. These CD4+ Treg 
accumulate in the tumour microenvironment, in response to IL-2 signalling. Activated 
effector T cells secrete pro-inflammatory cytokines and directly attack tumour cells. 
Treg inhibit activation of CD8+ T cells, hampering tumour killing and accumulation of 
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further inflammatory cells. Regulatory T cells moreover promote M2 polarisation of 
TAM via a IL-10/TGFβ signalling loop and inhibit dendritic cell (DC) activity (19).   
It has been shown that stromal cells – under the influence of Treg – actively work 
together to prevent direct contact between cytotoxic T cells and tumour cells (20). 
Besides immunosuppressive Treg, immature monocytes with immunomodulatory 
function – MDSC are among the major effectors of the tumour-promoting 
microenvironment. Their accumulation and function has been associated with the 
expression of S100A8/A9 (21). 
Together, tumour-induced Treg and MDSC impair the anti-tumour immune activity 
and promote tumour immune evasion (22). 
One particular strategy of cancer immunotherapy is to inhibit or block Treg function to 
unleash the anti-tumour immune response. It has been hailed the turning point in 
cancer therapy in a Science Editorial in 2013 (4), referring to very promising results of 
immunomodulatory therapy even in advanced cancer, refractory to conventional 
therapy. This could mark a paradigm shift in cancer therapy, refocusing from the 
primary tumour cell towards the tumour-promoting environment. However, a 
significant number of patients in phase I and II clinical trials did not respond to specific 
immunotherapy at all – possibly because of differences in composition of the tumour 
microenvironment. 
As the tumour microenvironment is still not fully understood with regards to 
components, their interplay and regulating factors, the precise mechanisms 
underlying the therapy effects or failure currently remain unknown.  Moreover, 
diagnostic medicine does not currently hold means for monitoring of early 
immunomodulatory therapy effects. By clinically established diagnostic methodology, 
effects on the tumour may not be detectable for several months. This is especially 
devastating as response to immunomodulatory treatment is currently difficult to 
predict, associated with inhomogeneous outcome and relatively frequent therapy 
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failure. Identification of the patients who will likely respond to tumour immunotherapy 
will be essential to foster success of future cancer therapy. 
Tumour-driven immune remodelling has also been implicated in the process of 
metastasis. Besides the aforementioned support of initial steps to metastasis – 
tumour cell migration and intravasation, variation in immune cell activity and function 
in distant tissue seems to precede and accompany systemic tumour spread. These 
tumour-mediated processes, leading to the establishment of a tumour-permissive 
environment in premetastatic tissue are summarised in the premetastatic niche (PN) 
concept.   
 
2.1.1 The premetastatic niche 
In the late 19th century, the English surgeon Stephen Paget discovered from the 
reevaluation of autopsy records that systemic tumour spread was not determined by 
physical distribution of tumour cells alone. He particularly hinted towards the 
discrepancy between blood supply and establishment of metastasis for instance in 
liver and lung (high frequency of metastasis) and spleen (low frequency of 
metastasis). He concluded that additional, tissue-specific factors must guide 
circulating tumour cells and built from that his ‘seed and soil’ hypothesis (23). Paget’s 
hypothesis still fits with modern metastasis research, now interpreting the seed as 
circulating tumour cell, cancer stem cell or progenitor cell and the soil as a 
microenvironmental niche, comprising multiple growth factors, stromal and immune 
cells in a neatly regulated interplay (24). 
The pre-metastatic niche is commonly characterised by stromal reorganisation and 
the infiltration of various immune cells (25), providing circulating tumour cells with a 
hospitable environment, protected from host immunity. 
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Figure 1: The premetastatic niche. 
Schematic illustration of the sequence of premetastatic niche induction. In response to tumour-secreted 
factors, myeloid cells are mobilised from the bone marrow and colonise potential target sites of 
metastasis, establishing a hospitable microenvironment for circulating tumour cells. The immune and 
stroma cells, assembled in the premetatastic niche support establishment of manifest metastasis. 
Illustration adapted from (26) 
 
As part of this mechanism, the entry of tumour cells into the niche is promoted by 
selective activation of the local vascular endothelium. After leaving the vascular 
space, the tumour cell is immersed in an extracellular matrix, prepared to foster 
tumour cell growth by supply of growth factors and growth promoting cell contacts 
including provision of active fibronectin. The vulnerable seed is protected from host 
immunity by an immunosuppressive microenvironment.  
Among the first cells entering the area of future metastasis are VEGFR1+ 
haematopoietic progenitor cells (27). These cells form clusters that precede further 
immune cell infiltration and tumour cell seeding and begin to remodel the local 
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microenvironment through induction of matrix metalloproteinases (MMP; prominently 
MMP9) and integrins. The cell clusters have been described as heterogeneous, 
comprising cells of various maturation states including CD117+ progenitor cells as 
well as CD11b+ monocytes and mature macrophages. 
The CD11b+ myeloid cells are a heterogeneous population of immature cells with 
immunomodulatory capabilities – MDSC, which seem to orchestrate further formation 
of the premetastatic niche (28) and promote the immunosuppressive function. The 
recruitment of immature myeloid cells and endothelial progenitors to the niche is 
driven by toll-like receptor 4 (TLR4) signalling, a multi-ligand receptor, activated by 
S100A8/A9 (29).  
Further components of the premetastatic niche include endothelial cells, driving the 
angiogenic switch in the metastatic lesion and mesenchymal cells, which develop into 
fibroblasts for the tumour (and metastasis) stroma. 
It is still not clear, how the premetastatic niche is regulated and installed and whether 
tumour cells are specifically guided to established niches or reach them by chance 
and due to the enhanced entry mechanism. 
Exosomes are currently being seen as a potential means of communication between 
the primary tumour and the target tissue of metastasis. Exosomes are small 
membrane vesicles, released by many cells in the human body. However, the delivery 
by tumour cells is vastly increased as compared to healthy cells. They contain 
proteins, mRNA and miRNA and have the potential to selectively alter recipient cells 
and the extracellular matrix in the target area.  
 
2.1.2 The role of MDSC in primary cancer and the premetastatic niche 
The tumour makes use of several mechanisms to suppress and evade the anti-
tumour immune response. Immunomodulatory Treg and MDSC accumulate in the 
tumour and actively inhibit anti-tumour action. MDSC accumulation has been 
associated with numerous factors including among others VEGF, GMCSF, 
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S100A8/A9 and CCL2 (30). MDSC are not a discrete cell population but much rather 
comprise a variety of cells in different stages of maturation and with different 
backgrounds: in mice as well as in humans, MDSC of granulocytic as well as of 
monocytic heritage have been described (31). The granulocytic MDSC present a 
Ly6G+Ly6Clow phenotype with high intracellular levels of reactive oxygen species 
(ROS) but virtually no nitric oxide (NO) while the monocytic MDSC is characterised as 
Ly6G-Ly6Chigh with high NO and undetectable ROS levels. The markers, shared 
across all subtypes of MDSC include Gr1 and CD11b. Various subtypes of MDSC 
have been described with CD115 and CD124 expression being related to 
immunosuppressive activity (32) 
Figure 2: MDSC are immature monocytes and granulocytes 
Schematic illustration of the differentiation pattern of MDSC in relation to precursors and mature cells 
without immunomodulatory function. Illustration from (33). 
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MDSC of all types share a common function and serve for orchestration of the 
immunomodulatory function in the premetastatic niche, although monocytic MDSC 
have been described to be generally more active than granulocytic MDSC. 
MDSC have been shown to nitrate T cell receptors (TCR), preventing their activation 
(34) and to moreover interfere with TCR-CD3 signalling, crucially required for full T 
cell activation (35). They moreover exert immunosuppressive effects via production 
and secretion of iNOS and Arginase and differentiate into tumour-promoting TAM 
under the influence of the tumour microenvironment (36) . 
MDSC accumulation in the premetastatic niche is mediated inter alia by the myeloid-
related protein heterodimer S100A8/A9 (37), member of the S100 protein family of 
calcium binding proteins. S100A/A9 is actively released by monocytic cells, upon 
activation and during differentiation and acts as a proinflammatory, intrinsic danger 
signal, promoting the accumulation of specific immune cell populations. MDSC induce 
expansion and local accumulation of Tregs and via this detour as well as directly 
suppress the anti-tumour immune activity of NK cells (38). MDSC have been shown to 
accumulate in the primary tumour in response to a variety of cytokines and soluble 
factors including granulocyte colony stimulatory factor (G-CSF) and TGFβ, released 
by tumour and/or non-tumour cells within the tumour microenvironment (39). MDSC 
express receptors for S100A8/A9 and initiate an autocrine loop to increase local 
levels of the heterodimer (40), which in turn increases MDSC accumulation. Up-
regulation of S100A8/A9 has moreover been found in the lung tissue of tumour-
bearing animals prior to establishment of manifest metastasis (41, 42). S100A8/A9 is 
secreted by myeloid cells either directly into the interstitium or as a major component 
of exosomes (43) and promotes the recruitment of CD11b+ myeloid cells to the 
premetastatic lungs (41, 42), which  must be interpreted as driving premetastatic 
niche establishment. 
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Figure 3: Immunomodulatory activity of MDSC 
The illustration summarises the interaction of MDSC with T cells, macrophages and NK cells in the 
tumour microenvironment to promote an immunosuppressive environment, permissive for growing 
tumours and establishment of metastasis. Illustration adapted from (33) 
 
The prominent role of MDSC in tumour-mediated immune remodelling inspired 
therapeutic targeting of MDSC expansion via e.g. eradication of MDSC-stimulating 
factors or MDSC function by inhibition of Arginase and iNOS. Moreover, promotion of 
MDSC differentiation into mature myeloid cells without immunosuppressive function 
by provision of Vitamin A or Vitamin D3 has been described (30). 
 
2.2 S100A8/A9 as a marker for immune cell activity 
S100A8/A9 is a heterodimer of the S100 family of calcium binding proteins, 
particularly released by activated phagocytes. It is involved in numerous intra- and 
extracellular processes (44) but was most prominently attributed a strong promoter of 
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inflammation and chemokine to immune cells, sensitively reflecting local phagocyte 
activity in inflammatory disorders.  
The family of S100 proteins is characterised by two calcium-binding-sites per 
molecule and comprises more than 20 members. S100 A8 (MRP8) and S100A9 
(MRP14) are specifically linked to innate immune functions by their expression in 
granulocytes, monocytes and early differentiation stages of macrophages. 
Intracellular, S100A8/A9 are involved in tubulin turnover, thereby controlling 
phagocyte migration (45). There is moreover evidence that these phagocyte specific 
S100 proteins are actively secreted in a tubulin dependent manner (46) during 
activation of the cell. 
 
 
Figure 4: S100A8/A9 release and action 
Schematic illustration of S100A8/A9 release upon activation of a resting monocyte by LPS, Il-1β or TNF. 
S100A8/A9 is actively transported to the cell surface through interaction with cytoskeleton components 
and released into the interstitium. Via binding of, among other receptors, RAGE and TLR-4, S100A8/A9 
exerts proinflammatory effects. Illustration adapted from (47).  
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They are in this role regarded as a damage-associated molecular pattern (DAMP) 
molecule, exhibiting kind of a double life: as intracellular molecules they have a role in 
cell homeostasis; after release to the extracellular compartment either passively, due 
to cell damage or actively during infections or inflammation, they become danger 
signals which activate immune cells and vascular endothelium (48, 49). 
Release of these molecules is specifically restricted to sites of vascular inflammation 
since secretion of S100A8/A9 is induced by contact of phagocytes with inflammatory 
activated endothelial cells. Therefore, various proinflammatory functions have been 
described for S100A8/A9: S100A8/A9 is an endogenous ligand for pattern recognition 
receptors RAGE and TLR4, binds to heparin sulfate proteoglycan and carboxylated N-
glycans on endothelial cells, and induces the production of pro-inflammatory cytokines 
and adhesion molecules on endothelial cells (50). 
Through the interaction with endothelial cells, S100A8/A9 stimulates the paracrine 
production of mediators to attract further CD11b+ myeloid cells, such as serum 
amyloid A (SAA) 3 in the pre-metastatic lungs (42).  
S100A8/A9 has been shown to act as endogenous ligand to TLR4, mediating the 
secretion of TNF and other proinflammatory, monocyte-specific cytokines (50, 51). 
They activate endothelial and immune cells; exhibit cytotoxic activities, have been 
described as chemotactic factors and promote adhesion and recruitment of 
leukocytes to sites of inflammation. S100A8/A9 are significantly overexpressed at 
sites of inflammation, in infections, autoimmune diseases and artherosclerotic plaques 
and are a sensitive marker for unstable angina pectoris. There is strong correlation of 
their serum concentrations to disease activity in many inflammatory disorders like 
Rheumatoid Arthritis (RA), Systemic Lupus erytematosus (SLE), Inflammatory Bowel 
Disease (IBD) or vasculitis (50, 52-55). 
In the context of juvenile arthritis, several reports identify S100A9 as superior indicator 
of inflammation activity compared to established markers of inflammation – a relapse 
of disease under therapy or after abortion of therapy is reflected by elevated serum 
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levels of S100A9 as early as three to four weeks before clinical symptoms occur (53, 
56, 57). The local tissue concentration of the S100A8/A9 complex in the area of 
inflammation and S100A8/A8 release has in this context been reported as up to 20-
fold higher as compared to the correlating serum level (49). 
The association between tumour development and increased immune cell activity in 
the tumour-supportive environment and the evidence for an involvement of 
S100A8/A9 in regulation of tumour-associated inflammation led to the evaluation of 
S100A8/A9 as a clinical tumour marker in various human cancers like prostate, 
gastric and colon cancer (58). Generally, high S100A8/A9 levels in tumour tissue or in 
serum seem to indicate a more rapid, aggressive course of disease (59, 60). Non-
invasive detection and measurement of exosomal S100A8/A9 release in potential pre-
metastatic sites would strongly promote the clinical utility of this marker. 
Recently, S100A8/A9 has been discussed as one of the bookmarking mediators of 
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Figure 5: S100A8/A9 in the context of malignant disease 
S100A8/A9 is released in the premetastatic lung environment, inducing hyperpermeability foci in the lung 
for easier extravasation of immune and tumour cells. It moreover acts as a chemoattractant for myeloid 
cells and promotes MDSC accumulation. Illustration adapted from (50). 
 
Ve cadherin+ endothelial cells and Mac1+ (beta 2 integrin CD11b/CD18) myeloid cells 
in lung tissue of tumour bearing mice have been shown to express high amounts of 
S100A8/A9 in response to tumour secreted factors that could include tumour 
exosomes (41). S100A8/A9 is believed to, directly (62) or via promotion of soluble 
factors such as TNFα, TGFβ and MIP2 (63), activate endothelial cells and recruitment 
of lymphocytes (64). These factors in turn signal for the circulating tumour cells to 
leave the blood stream and to seed into the prepared niche. 
The crucial role of S100A8/A9 for cancer development and spread has been 
underlined by recent studies, showing S100A9 knock-out mice to have significantly 
decreased numbers of tumour-promoting myeloid derived suppressor cells, reduced 
rates of metastasis and an increased overall survival (37) as compared to wild-type 
mice. 
	   23 
A correlation between serum S100A8/A9 and failure of tumour immune therapy 
response has been established in retrospective studies (65); in murine breast cancer 
models, the density of S100A8/A9+ cells in the tumour was associated with a more 
aggressive tumour development and reduced clinical outcome (66). S100A8/A9 has 
also been directly targeted for therapeutic purposes. The small molecule Tasquinimod 
binds S100A9 and induces a conformational change of the heterodimer, apparently 
preventing S100A8/A9 from effectively binding certain target receptors. In clinical 
trials, the consecutive inhibition of S100A8/A9 signalling had positive outcome effects 
in prostate cancer (67) and breast cancer (68), probably through revision of 
S100A8/A9-mediated tumour-promoting immune modulation (69, 70).  
In both roles – as a marker for immune cell activity in inflammation and cancer as well 
as a therapeutic target for inhibition of pathologic immune activity, S100A8/A9 has a 
strong potential. 
 
2.3 Molecular imaging 
Per definition by the Society for Nuclear Medicine and Molecular Imaging, molecular 
imaging is “the visualisation, characterization, and measurement of biological 
processes at the molecular and cellular levels in humans and other living systems“ 
(71). This can be achieved via various ways and includes imaging approaches of 
multiple scales, ranging from microscopy systems to clinical whole body scanners. 
Modalities for whole body molecular imaging include magnetic resonance imaging 
(MRI), planar or tomographic optical imaging (OI) and radionuclide-based techniques 
positron emission tomography (PET) and single photon emission computed 
tomography (SPECT). Usually, the different imaging techniques require the use of 
specific contrast agents for visualisation of molecular and physiological processes.  
Three major types of contrast agents can be defined by their principle of action (72): 
1. Perfusion type contrast agents distribute with the blood pool without 
specifically binding target structures in tissue or the vasculature. Perfusion 
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type contrast agents enable measurement of perfusion and pathological 
variation of perfusion including hyperaemia in inflammation or highly 
vascularised cancer lesions. Measurement of local extravasation of perfusion 
type contrast agents also allows for estimation of vessel wall integrity as an 
indicator of pathological processes. 
2. Target-specific probes are characterised by a binding moiety, specifically 
addressing a structure, present in the target tissue. This structure can be a cell 
surface marker as well as a soluble factor or extracellular matrix component. 
Even intracellular structures can be targeted with appropriate probes, able to 
penetrate the cell membrane. Target-specific probes comprise – aside from 
the binding moiety – a label, respective of the chosen imaging modality. 
3. Activatable or smart probes are inactive and do not emit as signal, detectable 
by the chosen imaging modality until they interact with the target structure. 
Activatable probes therefore offer the highest signal-to background ratio of all 
probes, as the unbound contrast agent in the blood pool does not contribute to 
the unspecific background noise. The relatively complex chemistry behind 
probes with variable signal characteristics limits the use to few applications 
like visualisation of enzyme activity. 
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Perfusion type contrast agents (A) distribute with the blood flow and indicate perfusion and 
vascular integrity without specific target binding. Target-specific contrast agents (B) comprise a 
binding moiety and a signalling component and specifically accumulate in areas of high target 
expression. A considerable unspecific background is constituted by unbound tracer. Activate-
able probes (C) change their signalling capacity upon interaction with the target molecule and 
therefore do not exhibit unspecific background signal. Illustration modified from (72). 
 
Probes of all three classes have been presented for all common imaging modalities. 
For specific visualisation of disease markers, targeted probes are still the most 
commonly used, and the chemistry behind labelling targeting molecules is well 
established. 
In this study, we aimed for establishment of a targeted imaging technique for immune 
cell activity-associated markers using this straightforward technical approach. 
 
Figure 6: Different types of contrast agents. 
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2.3.1 Principles of target-specific imaging 
Various different molecules – both natural and artificial – exhibit the potential to 
specifically bind target structures in biological systems, thereby qualifying in principle 
as the backbone of a target-specific imaging probe. 
The most prominent among binding molecules certainly are antibodies of the 
immunoglobulin G (IgG) type. Over the past decades, the discrimination properties of 
antibodies have been used to establish methodology, essential for current research: 
ELISA, FACS and immunohistochemistry evenly rely on the specificity of antibody-
target binding. Antibodies have moreover been successfully established as molecular 
therapeutics and – in preclinical settings – highly versatile imaging agents (73). IgG is 
widely conserved across mammals and of very similar structure even between mice 
and humans. A full length IgG has a size of around 150 kDa and is assembled of four 
subunits, two identical light chains and two identical heavy chains. The size of 
antibodies renders the possibility of random labelling – conjugating the antibody with a 
signalling molecule without changing binding affinity or in vivo distribution of the 
compound as compared to a naïve antibody. However, recombinant antibodies can 
be engineered for site-specific labelling for even easier and quicker tracer preparation. 
Some animals, among them camels and sharks, present with more ancient, archaic 
antibodies, comprising a less complex structure. The antibodies of camelidae for 
example do not confirm the IgG structure but lack light chains, reducing the overall 
size to less than 90 kDa (74).  
From intact IgG, several fragments can be isolated and recombinantly fused.  The 
isolated fragments, responsible for antigen binding can be as small as 15 – 20 kDa. 
The size is of major importance for the tracer distribution in biological, living systems 
as it essentially determines the tracer ability to extravasate and penetrate stromal 
tissue as well as the elimination route. Smaller compounds generally show a faster 
tissue penetration and moreover do not require vascular integrity to be disturbed. 
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Bigger compounds require more time or active transport mechanisms to reach 
stromal, extravascular targets.  
The major elimination routes from the body are the kidneys for compounds, smaller 
than about 30 kDa, and the liver for bigger compounds. Renal elimination is 
considered to be much faster, clearing circulating compounds within hours, while 
hepatic elimination of circulating compounds can take days or even weeks. The blood 
pool level of a specific contrast agent on the one hand determines the unspecific 
background signal, exerted by circulating tracer that has not specifically bound the 
target structure (yet) and on the other hand exposes the body to the label – in the 
case of radionuclide-driven tracers to radioactivity. A longer circulation time of bigger 
tracers therefore constitutes a more intensive exposure of the recipient to radioactivity 
with all the consecutive risks and a longer delay between tracer application and the 
reduction of the unspecific background signal to a level that would reasonably allow 
for identification of specific tracer accumulation. 
For the more rapid accumulation in the target area and faster elimination from the 
blood pool, smaller compounds are generally regarded more favourable for in vivo 
application. The rapid distribution enables for examination shortly after tracer 
application. For some targets – especially those, located extravascular and thus more 
difficult to reach for circulating tracers, additional features of the targeting moiety and 
the label come into play – the distribution across extravascular body compartments 
can be influenced by the charge/polarisation as well as lipophilicity and/or 
hydrophilicity of the compound. Additionally, binding affinity and specificity or potential 
cross reactivity determine the quality of an in vivo imaging signal.  
Antibodies naturally provide a high binding affinity and target specificity. Their 
relatively big size enables for very easy labelling approaches but also demands 
specifically tailored imaging approaches due to long circulation time and consecutively 
high unspecific background, early after administration. Ideally, a tracer would provide 
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the binding characteristics of an antibody with the biodistribution and elimination of a 
smaller molecule. 
The individual choice of a tracer molecule depends on availability of high-affinity, 
highly specific targeting moieties and accessibility of the target structure. Depending 
on the tracer molecule, different labels for appropriate imaging modalities can be 
considered. 
 
2.3.2 Molecular imaging modalities for target-specific imaging 
Given the availability of a specific contrast agent, all in vivo imaging modalities 
basically qualify for in vivo molecular imaging. Some approaches, however, are more 
suited for particular studies than others. 
In MRI, signal is generated through the interaction of electromagnetic fields with 
nuclei such as the protons in the water molecule. In addition, image contrast is mainly 
affected by relaxation processes, which can be influenced by contrast agents. 
However, the overall effect of contrast agents is moderate, resulting in a relatively low 
sensitivity to detect specifically labelled agents. Therefore a high local concentration 
of contrast agent is required for reliable detection, widely precluding MRI from use for 
targeted imaging.  
Only OI and radionuclide-mediated methods offer sensitivity in the nanomolar range, 
enabling for detection of local tracer accumulation. 
 
2.3.2.1 Fluorescence-mediated imaging approaches 
OI relies on the use of near-infrared light as carrier of diagnostic information. As 
opposed to light of the visible spectrum, near-infrared (NIR) light penetrates tissue up 
to a couple of centimetres of depth due to lower absorption in tissue. At the same 
time, the autofluorescence of tissue is relatively low in the NIR range of the spectrum. 
Fluorescent dyes have initially been developed for fluorescence microscopy but 
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Figure 7: Absorption coefficient in relation to the optical spectrum. 
The graph shows the absorption coefficient for distinct wavelengths, illustrating that light of the near-
infrared range (<650 nm) faces less absorption and therefore penetrates tissue better than light of shorter 
wavelength. The insert shows the tissue autofluorescence. From (75) 
 
Fluorescent dyes require excitation by light of discrete wavelength. The excitation light 
is absorbed by the dye and transformed, resulting in emission of lower energy light by 
the dye. This emission can be recorded at video rate by dedicated camera systems 
and provide sensitive high resolution imaging of the dye distribution. Fluorescence 
reflectance imaging (FRI) systems, combining emission light source and detector in 
an arrangement, similar to a camera with flash light, detect the surface signal, 
originating from the specimen upon excitation. 
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Figure 8: Principle of Fluorescence Reflectance Imaging 
For FRI, a simple set up of light source and a filter-equipped camera is required. Upon illumination of the 
target structure, i.e. the animal, and consecutive excitation of the fluorescent dye, emitted light is 
collected by the camera. Specific filters ensure that only the emission of the elicited dye is collected and 
reduce recording of unspecific background fluorescence. Illustration from (76) 
 
Due to scattering and absorption of the emitted fluorescence signal, detection by 
conventional camera systems is limited to a couple of millimetres of depth in living 
tissue. Moreover, scattering, absorption and the theoretical possibility of single 
signalling molecules being excited and detected multiple times hamper quantification 
of optical imaging signals and thorough internal controls are needed for validation of 
in vivo observations. 
Tomographic approaches have been established to overcome these limitations. Basic 
fluorescence-mediated tomography (FMT) systems combine multiple excitation light 
sources and detectors in a gantry-like arrangement around the specimen and 
calculate the 3D position of a NIRF source from the signal pattern across the gantry. 
A mathematically more sophisticated approach uses data from near-planar, multi-
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angle imaging to calculate the in vivo distribution of fluorescence tracers in a small 3D 
volume. 
Based on phantom experiments with fluorescent light sources in defined depths of 
absorbing and scattering tissue, commercially available FMT systems promise full 
quantification for all fluorescent dyes they have been calibrated for. Although this 
promise has been contested recently, leading to some uncertainty as to the real 
potential of FMT for reliable quantification, it still is the only imaging approach for fast 
and easy in vivo 3D imaging of fluorescent tracer distribution in deeper tissue sections 
(of laboratory animals). In hybrid imaging approaches, the additional use of either CT 
or MRI data for image reconstruction and normalisation of the functional fluorescence 
data increases the image data quality. For this study however, a simple, fluorescence-
only FMT system was used and to circumvent discussion on the precision and validity 
of quantitative FMT data has only been used for visualisation of tracer distribution in 
the tumour area. 
 
 
Figure 9: Exemplary set up of a Fluorescence Mediated Tomography system. 
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Data from a sequence of planar scans after illumination of the specimen from various angles allows for 
reconstruction of fluorescence dye distribution within the specimen. From (77) 
 
Tracers for in vivo OI can usually serve as signalling molecules for Fluorescence 
Activated Cell Sorting (FACS) and fluorescence microscopy as well, enabling 
immediate correlation of in vivo imaging results.  
Common dyes for NIRF imaging include cyanine dyes with excitation/emission 
maxima in the NIR range of the spectrum. These dyes are commercially available as 
active esters for quick and easy labelling of proteins or similar compounds. In contrast 
to other fluorescent dyes cyanine dyes do not bleach quickly, providing constant NIRF 
for in vivo application.  
 
2.3.2.2 Radionuclide-mediated imaging approaches  
Radionuclide-mediated imaging approaches use the energy, emitted in the context of 
radioactive decay for generation of image information. The two techniques, 
established for in vivo imaging are PET and SPECT. Both methods offer tomographic, 
three-dimensional information on radionuclide distribution within the specimen but 
differ with regards to detection method and suitable isotopes. 
PET imaging is based on indirect measurement of positron-emission by isotopes that 
undergo β+ decay. The released positron travels for a short distance in tissue, 
thereby decelerating, and annihilates with an electron. The energy, released during 
this annihilation is emitted as a pair of annihilation γ-photons, travelling in virtually 
opposite (179.5°) directions. These γ-photons can be detected by a circular gantry 
and allow for retrospective localisation of the annihilation event, virtually identical with 
the localisation of the isotope. To increase the sensitivity of PET scanners scintillators 
potentiate each detected photon before the event is recorded by photomultipliers. 
Only those photons can be used for reconstruction of isotope distribution patterns that 
arrive the gantry in pairs, which is also called coincidence detection. The detected 
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events at different detector positions on a circular gantry result in projections, enabling 
the reconstruction of the distribution of activity.  In addition, the travel time difference 
between the two opposite detectors can be exploited to improve image quality. Spatial 
and temporal resolution of PET imaging are determined by the design of the gantry 
and arrangement of detectors as well as the reconstruction algorithm and the energy 
of the radioisotope’s emission protons, as higher energy protons travel further in 
tissue before annihilating with an electron, thereby increasing the distance between 
the location of the isotope/tracer and the location of the detected event. 
 
 
Figure 10: Principle of Positron Emission Tomography Imaging. 
Upon radioactive decay of β-emitters, positrons (β+) are released and annihilate with electrons (e-). In 
result of the annihilation, two identical photons are sent out in virtually opposite direction. Recording of 
these photons on a circular gantry allows for reconstruction of the emitter distribution in the target 
volume. Image courtesy of Dr Thuy Tran, Lund University Bioimaging Center, Sweden 
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Radioisotopes, suitable for PET include 18F, 11C and 68Ga. The relatively short half-life 
of these isotopes, ranging between around 20 min (11C) and 110 min (18F), demands 
tracer compounds of rapid biodistribution for effective imaging. Intact IgG would not 
have accumulated in the target area and especially have not cleared from the blood 
pool by the time the isotope has decayed to a degree below the detection sensitivity 
of PET. An exception among common PET-suitable isotopes is 89Zr with a half-life of 
78 h. It is increasingly used as radiolabel for antibodies in clinical immune-PET 
applications (78). 
SPECT is based on direct detection of γ-rays, emitted during the decay of isotopes 
like 111In, 99Tc or 123I. These isotopes are characterised by a generally longer half-life 
than typical PET isotopes. The half-life of 111In is 67 h, enabling – just as 89Zr – for  
labelling of e.g. intact IgG and following the tracer over several days after application. 
To obtain SPECT images of γ-decay, a gamma camera is rotated around the object 
and planar images of γ-radiation are acquired. The gamma-camera consists of 
collimator in front of detector elements to measure perpendicularly arriving γ-rays.  
Therefore, the spatial resolution depends strongly on the set-up of the collimator and 
high-resolution imaging of small animals is possible. Multiple projection images are 
then retrospectively combined for calculation of a three-dimensional dataset, following 
algorithms, similar to those from computed tomography. Typically, the camera is 
rotated a full 360° around the specimen and images are acquired every 3-6° for ideal 
coverage of the object.  
The sensitivity of SPECT is slightly lower than PET due to the use of a collimator. 
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Figure 11: Principle of Single Photon Emission Computed Tomography. 
Some isotopes emit γ-rays during radioactive decay. Collection and recording of these photons by a 
circular gantry or a circulating γ-camera allows for reconstruction of the γ-ray source distribution within 
the target volume. Image courtesy of Dr Thuy Tran, Lund University Bioimaging Center, Swede 
2.4 Previous work on S100A8/A9 imaging 
Target-specific in vivo S100A8/A9 optical imaging has recently been established for 
sensitive and specific monitoring of monocyte activity in local inflammation (79) and 
primary cancer lesions (80) using a fluorescence labelled antibody. Both publications 
can be found in the annex to this thesis.  
Briefly, from a polyclonal antibody, targeting S100A9 (aS100A9), a fluorescent tracer 
has been synthesised, which has been successfully tested in vitro and in vivo. It could 
be shown that S100A9 is a versatile marker for inflammatory activity in exemplary 
models of disease, representative of different inflammatory stimuli and pathologic 
pathways. Specifically, the monitoring of local inflammation using S100A9 as 
molecular target for optical imaging has been established: We were able to show that 
a fluorescence labelled antibody, targeted on S100A9, allowed for specific 
visualisation of S100A9 release by activated immune cells in areas of inflammation. In 
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vivo imaging was validated using immunohistochemistry of inflamed tissue, showing 
S100A9 to be associated with activated monocytes in areas of inflammation. 
Moreover, dual injections were performed with aS100A9 and a rabbit-derived IgG 
(rabIgG) without relevant specificity in mice. Labelled for different excitation and 
emission wavelength, these dyes could be differentiated in vivo with the rabIgG 
representing perfusion and unspecific binding mediated background signal. Different 
distribution patterns suggested a specific accumulation of the S100A9-detecting 
tracer. We repeated the experiments in S100A9-/- mice (complete knock out). While 
rabIgG mediated signalling was virtually unchanged, the accumulation of aS100A9 
dropped to levels, equivalent to unspecific background distribution. S100A9 in vivo 
imaging positively correlated with S100A9 serum levels. 
In selected models of inflammation and immune activation such as arthritis and 
infectious disease, the predictive value of S100A8/A9 imaging could be demonstrated 
by establishing a correlation between in vivo imaging and disease development and 
outcome: Different models of arthritis have been established and examined using 
optical S100A9 imaging. In collagen induced arthritis in BALB/c mice, a stable, strong 
inflammation could be observed after challenge by clinical examination and in vivo 
imaging; the severity of inflammation, reflected by clinical grading, strongly correlated 
with in vivo S100A9 imaging. In a second step, we induced arthritis in Bl6 mice that 
exhibit a heterogeneous, clinically unpredictable response to the challenge. S100A9 
imaging allowed for prediction of the course of disease as early as seven days after 
arthritis induction. In a model of local infection, S100A9 imaging at early stages after 
infection allowed for identification of an effective, Th1 driven immune response, 
representing the first in vivo marker for Th1/Th2 dichotomy. 
The severity of inflammation and in vivo imaging could also be correlated for allergy, 
inflammatory bowel disease (81) and LPS induced lung inflammation. 
The in vivo imaging could be shown to closely reflect local S100A8/A9 release: Serum 
was acquired at different time points during development of inflammation and parallel 
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to imaging. By ELISA, S100A9 was quantified and correlated with in vivo imaging 
results. Where applicable, we collected material for determination of local S100A9 
levels. In models of infection, the infected hind paws were flushed and the resulting 
liquid was assessed for cellular infiltrate, pathogen and S100A9 (79). In lung 
inflammation, BALF was collected; in arthritis, synovial fluid was collected. Specific 
imaging sensitively reflected the local S100A9 levels and correlated well with systemic 
levels of the protein. This suggests an integrated diagnostic approach, combining an 
easy accessible serum test for stratification as to which patient might benefit from a 
specific scan to localise and differentially monitor multifocal disease (79). 
Having used optical fluorescence imaging only, these studies were limited to 
superficial foci of immune cell activity such as the primary tumour lesion.  
For application of S100A9 imaging to visualise the systemic influence of cancer on the 
immune system and the potential activity of immune cells in the context of 
premetastatic tissue priming, the physical limitation of optical imaging may hamper the 
collection of sufficient, systemic information. Moreover, imaging beyond the preclinical 
mouse model system would be precluded. 
 
2.5 Purpose of this project 
The aim of this thesis is to prove the suitability of S100A8/A9 to serve as a marker for 
tumour-associated immune remodelling in the context of primary malignant disease 
and systemic tumour spread.  
Beginning with optical imaging of the immune cell activity in the primary tumour, 
methodology for visualisation of systemic tumour effects will be investigated. Building 
on the aforementioned optical imaging approach, S100A9-specific SPECT imaging 
will be developed to explore the potential of S100A9 as a translatable diagnostic 
imaging marker. This S100A9-specific SPECT imaging will be tested in a murine 
model of metastatic breast cancer to investigate in vivo visualisation of systemic 
tumour-mediated effects on monocyte activity, assessing S100A8/A9 as a surrogate 
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marker for tumour-mediated immunomodulation in the context of premetastatic lung 
tissue priming. The specific objectives of this project are 
1. To establish S100A8/A9 as a marker for local tumour-immune interaction  
(Chapter 3) 
Optical imaging for specific detection of S100A8/A9 release will be used to 
identify regional changes in immune cell activity and tumour-associated 
inflammation in the primary tumour. Furthermore, the correlation of S100A8/A9 
activity in the tumour microenvironment with tumour aggressiveness and 
growth will be investigated. Analysis of the cellular composition of such foci will 
serve for validation of the in vivo imaging results.  
2. To develop a S100A9-specific radiotracer 
(Chapter 4) 
The fluorescent optical imaging tracer is limited to superficial, focal imaging. 
For evaluation of systemic S100A8/A9 release, indicative of the systemic 
tumour-immune interaction, a radiotracer for SPECT application will be 
produced.  
3. To establish systemic S100A9-specific in vivo imaging in cancer 
(Chapter 5) 
The aforementioned S100A9-specific SPECT tracer will be used for 
visualisation and measurement of tumour-immune interaction in the tumour 
microenvironment and distant tissues. The effects of malignant disease on the 
immune cell activity in distant target tissue of metastasis will be examined and 
cellular processes, underlying the in vivo imaging signal will be identified.   
4. Understanding pre-metastatic niche establishment 
(Chapter 5) 
The imaging methodology, established within this project, will enable studying 
of mediators and regulators of tumour-immune interaction and tumour-
	   39 
mediated tissue priming. The effects of inhibition of the CCL2/CCR2 signalling 
axis will be studied exemplarily.  
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3 Optical S100A9 imaging in the primary tumour 
environment 
 
Contents, presented in this chapter, have in part been published in the Journal of 
Nuclear Medicine in May 2015 under the title “Optical In Vivo Imaging of the Alarmin 
S100A9 in Tumour Lesions Allows for Estimation of the Individual Malignant Potential 
by Evaluation of Tumour-Host Cell Interaction“(82). The full text of the publication can 
be found in the Annex (9.2). 
 
As an initial step towards understanding of tumour immune interaction and 
establishment of a diagnostic tool for non-invasive measurement of these processes, 
the aforementioned method for visualisation of local inflammation has been adapted 
for the visualisation of tumour-associated immune cell activity in subcutaneous tumour 
models. 
As mentioned already, tumour-associated myeloid cells and their offspring, including 
immature monocytes like MDSC and macrophages are highly abundant in the tumour 
microenvironment. They contribute to local growth and invasion by degradation of 
ECM, sustenance of tumour vitality by promoting neoangiogenesis and tumour 
immune evasion via suppressive interaction with host immunity. 
In this study, S100A8/A9 imaging is established as a tool for non-invasive 
visualisation and measurement of tumour-associated monocyte activity as an 
indicator of malignant development and growth. Due to the nature of fluorescence-
mediated imaging, this preliminary study was confined to imaging of tumour immune 
interaction in the subcutaneous tumour lesion itself.  
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3.1 Material and Methods 
3.1.1 Murine breast cancer model 
The murine breast cancer cell lines 4T1 and 67NR share the genetic background of a 
common maternal cell line, derived from a Balb/c mouse, and were used for tumour 
induction as an established syngeneic model system of graded malignancy (83). The 
specific characteristics of the tumour cell lines include differences in the metastatic 
potential: While 4T1 tumours induce metastasis in lungs and bone via 
haematogenous dissemination and invade the local lymph nodes within weeks, 67NR 
cells grow only locally.  
Cells were cultured and harvested according to established protocols (83).  
Female Balb/c mice were obtained from Charles River UK and housed in a dedicated 
Biological Services Unit under controlled conditions (regular 12 h day/night rhythm, 
controlled temperature) and chow and water ad libitum. The cage bedding was extra 
soft paper bedding to avoid irritation of the local tumour site. After delivery, mice were 
allowed to rest for at least two weeks before interventional procedures were initiated. 
To control for a contribution of the tumour cells to local S100A9 levels and to prove 
specific tracer to target binding, S100A9-/- mice with Balb/c background were 
inoculated with 4T1 cells accordingly and underwent the same imaging procedure. 
The knock out mice were developed and bred at the Institute of Immunology, 
University of Münster, and provided as part of a collaboration. Characteristics of the 
knock out mouse have been described in detail earlier (84).  
 
On the day of tumour inoculation (d0), cells were harvested by trypsination, washed, 
resuspended in PBS and kept on ice for further use. 1.5x106 cells were suspended in 
50 µl PBS and implanted into mice either subcutaneously over the flank or 
orthotopically into the mammary fat pad. Tumour size was measured daily. 
All imaging experiments were performed tumour size dependent (4 - 6 mm) to reduce 
the influence of differences in tumour growth between cell lines or mouse strains (85). 
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For assessment of the predictive potential of S100A9 imaging, animals were kept 
after in vivo imaging and the tumour growth was monitored over the following 8 - 10 
days. 
To control for the influence of tumour-primed MDSC on the local tumour development 
and potential consecutive effects on the in vivo imaging signal, splenic monocytes 
were harvested from tumour-bearing or healthy animals. Monocytes, including MDSC, 
were identified by FACS according to the expression of Gr-1 and CD11b. Mice 
received an i.v. injection of isolated cells from either tumour-bearing mice (tMDSC) or 
healthy controls (IMC) and were subsequently implanted with 4T1 tumours as 
described before. Imaging was performed at day 8 after tumour inoculation 
immediately after tracer injection and 24 h later. 
 
3.1.2 Fluorescence tracer for S100A8/A9 
A rabbit polyclonal antibody, targeting the S100A9 subunit of the S100A8/A9 
heterodimer was labelled with the fluorescent dye Cy5.5 as described in detail before 
(79). The antibody addresses a specific epitope of the S100A9 protein (86) that is 
conserved across different species including mice and humans and does not interfere 
with the protein function. In this context, the polyclonal antibody proved different from 
commercially available S100A9 antibodies which did either lack specificity for human 
or murine S100A9 respectively, exhibited an overall reduced binding affinity or an 
increased cross reactivity with other S100 proteins. The identical polyclonal antibody 
that has been used for the in vivo imaging experiments also forms the basis of the 
validation experiments in ELISA, FACS and immunohistochemistry, therefore 
enabling for direct control of in vivo imaging data.  
As a control for unspecific tracer distribution due to perfusion and e.g. Fcγ receptor 
binding, a polyclonal rabbit antibody against a target, irrelevant in mice (goat serum) 
was used. The size of the antibodies was virtually identical, as was the genetic 
background of the host animals. 
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Briefly, the rabbit-derived antibodies addressing S100A9 or control IgG, were purified 
via protein G-sepharose and labelled with the fluorochromes Cy5.5 or Cy7 according 
to the manufacturer’s instructions (GE Healthcare, Uppsala, Sweden): 5 mg of the 
respective antibody was dialyzed against 100 mM Na2CO3 buffer, pH 8.0, and a 20-
fold molar excess of the fluorochrome was added for 90 min at room temperature. 
The resulting tracer was purified from unbound dye by size exclusion chromatography 
using a PD10 column. The labelling efficacy (dye/antibody ratio) was determined on 
the basis of UV-spectra of the purified dye-antibody-compound, using PBS as a 
reference buffer. The labelling for the experiments described here resulted in 2.5 – 3.0 
fluorochrome molecules per antibody, irrespective of the precursors. 
The tracer was stored at 4°C and protected from light to avoid bleaching. In 
accordance with prior experience on the use of the tracer for visualisation of local 
inflammation, a dose, equivalent of 2 nMol dye was administered 24 h prior to 
imaging. The imaging time point was chosen on the basis of prior experiments in local 
inflammation (79), where we observed the highest target-specific tracer accumulation 
at about 24 h after tracer administration. 
 
3.1.3 In vivo optical imaging 
Imaging studies were performed using either FRI or FMT imaging systems. 
For in vivo OI, a FRI system (In-Vivo FX PRO, Bruker BioSpin, Millerica, MASS, USA) 
was used. Excitation light was adapted according to the dyes to 630 nm (Cy5.5) or 
730 nm (Cy7) respectively. The resulting emission was recorded at 700 nm or 790 
nm, using a filter-equipped, high-sensitive CCD camera. Signal acquisition time was 5 
- 30 s for fluorescence images. White-light images were acquired for anatomical 
orientation.  
FMT was used for 3D visualisation of dye distribution in the target region. The free 
space flat panel FMT device (In-vivo Imaging System FMT 2500, FMT 2500 Imaging 
Software, Vers. 1.1.1.3, both Visen Medical, now Perkin Elmer, Waltham, MASS, 
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USA) allowed for reconstruction of three-dimensional data from fluorescence signals 
at 680 and 750 nm for visualisation of Cy5.5 or Cy7 (87, 88). Scanning time of the 
tumour region was around 4 minutes.  
Mice were held under inhalation-anaesthesia (2.0% Isoflurane in air) during 
examinations. 
For image analysis, a region of interest (ROI) was placed to cover the whole tumour 
area as depicted on white light images. FRI data were presented as mean photon 
counts, normalized for the ROI area, in arbitrary units (AU). From each dataset, mean 
values and standard deviation were calculated. 
For the treatment study, scans were performed immediately (0 h) and 24 h after tracer 
injection. From these values a ΔFluorescence Intensity (ΔFI) was calculated as:  
ΔFI = signal from the target ROI at 24 h – signal from the target ROI at 0 h. 
After in vivo imaging, animals were sacrificed and organs were harvested for 
correlative ex-vivo examination of dye-distribution using FRI; tumour tissue was 
harvested for FACS and/or histology. 
 
3.1.4 Ex vivo validation of fluorescence imaging results 
The resected tumours were divided, and equal amounts of tissue were processed for 
immunohistochemistry and FACS respectively. For FACS, single cell suspensions 
were produced from tumour tissue and stained for S100A9 and CD11b with 
corresponding isotype controls. 
Monocyte specific staining was performed using an APC-labelled ratCD11b antibody 
(eBioscience, San Diego, CA, USA); S100A9 specific staining with a polyclonal 
S100A9 antibody and FITC labelled goat-anti-rabbit secondary antibody (Jackson 
Immunoresearch Europe, Newmarket, UK). Non-specific rabIgG and APC-labelled 
rabIgG (eBioscience) were used as controls. FACS data were gated according to size 
and granularity to exclude cell detritus. Isotype controls served for adjusting individual 
FACS measurements. All FACS measurements were conducted using a FACSCalibur 
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system and analysed using the CellQuest Pro software (both BD Biosciences, 
Franklin Lakes, NJ, USA). Data were presented as cell frequency reduced by the 
individual isotype control to exclude unspecific staining.  
For histology, tissue was paraffin embedded and cut. Tumour sections were stained 
for S100A9 and F4/80 (macrophages) for direct correlation of imaging findings. All 
stainings were carried out according to established protocols (49, 89). 
Moreover, lysates from resected tumours, tumour cells from tissue culture and tissue 
culture supernatant were analysed for S100A8/A9 using a specific, in house 
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3.2 Results 
3.2.1 Tumour lesions specifically retain aS100A9-Cy5.5 
 
Figure 12: S100A9 optical fluorescence imaging in 4T1 tumour-bearing animals 
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To prove the specificity of tracer to target binding and to control for unspecific tracer 
accumulation (e.g. perfusion-related or FcγR-mediated), 4T1 tumour-bearing mice 
were injected with aS100A9-Cy5.5 or rabIgG-Cy5.5. Imaging experiments were 
conducted at a constant tumour size of 5 mm and ROI size was identical for all 
experiments. FRI revealed a significantly higher signal after injection of the specific 
probe than after injection of equal amounts of rabIgG-Cy5.5 (2430 AU vs. 1240 AU; 
p < 0.001, n = 16/12). In S100A9-/- mice, injection of aS100A9-Cy5.5 resulted in 
signals, comparable to the rabIgG-Cy5.5 mediated signal in wild type animals 
(950 AU; n = 5) . In ex vivo biodistribution studies, resected organs were analysed for 
fluorescence signals and a significantly higher fluorescence in the tumour after 
injection of aS100A9-Cy5.5 than rabIgG-Cy5.5 could be verified. Tumour to non-
target tissue ratios (kidneys, muscle) were significantly higher for aS100A9-Cy5.5 
than for rabIgG-Cy5.5 (aS100A9-Cy5.5 vs. rabIgG-Cy5.5 tumour/kidney: 3.2 vs. 2.1; 
p ≤ 0.001; tumour/muscle: 3.76 vs. 2.4; p ≤ 0.05). 
 
 
Figure 13: Fluorescence-mediated tomography imaging after parallel injection of aS100A9-Cy5.5 
and rabIgG-Cy7. 
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The FMT scan at 750 nm for Cy7-labelled rabIgG reveals a homogeneous distribution over the 
subcutaneously over the flank implanted 4T1 tumour, reflecting perfusion. At the same time, aS100A9-
Cy5.5 accumulates in specific tumour areas only. 
  
After parallel injection of aS100A9-Cy5.5 and rabIgG-Cy7, FMT allowed for 
simultaneous evaluation of the distribution of both tracers. While rabIgG-Cy7 showed 
a homogeneous distribution over the whole vital tumour area, aS100A9-Cy5.5 
accumulated in delineated hot-spot areas, predominantly located in the periphery of 
the tumour (right panel). TAMs within clusters of S100A9+ cells could accordingly be 
defined by histology. 
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3.2.3 Tumour-associated inflammation supports tumour growth 
CD11b+ cells as an apparent source of S100A9 in the tumour microenvironment were 
isolated from the spleens of either tumour-bearing (incl. tumour primed MDSC – 
tMDSC) or healthy mice (naïve, immature myeloid cells – IMC) and transferred into 
animals, which were thereafter inoculated with 4T1 (schematic representation of the 
protocol in Fig 12). 
 
 
Figure 14: Growth rate and local S100A9 imaging signal in 4T1 tumour lesions after treatment 
with tMDSC or IMC 
Mice received intravenous injections of tumour-primed MDSC (tMDSC; dark grey; n=10), isolated from 
tumour-bearing animals or immature myeloid cells (IMC; striped; n=10) from healthy animals or no 
additional cells (control; white; n=5) prior to implantation of 4T1 tumours. The growth of the tumour was 
monitored. When the tumours reached a diameter of 5 mm, mice were injected with aS100A9-Cy5.5 and 
FRI was performed immediately after tracer injection and 24 h later. The growth rate of tumours was 
significantly accelerated in mice that received tMDSC (*=p<0.05; **=p<0.01); application of naïve IMC 
had no measurable effect on the tumour growth. The accumulation of aS100A9-Cy5.5 was similarly 
elevated in tMDSC-treated mice as compared to controls or mice that received IMC (***=p<0.001). 
 
The average tumour growth in animals, transferred with tumour primed CD11b+ cells 
including tMDSC was significantly accelerated as compared to mice after transfer of 
monocytes from healthy controls (average relative tumour size on day 8 as compared 
to day 1 tMDSC vs. IMC: 316% vs. 228%; p = 0.001). This was also reflected by in 
vivo imaging: S100A9 fluorescence was significantly higher in mice after transfer of 
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tMDSC and consecutive accelerated tumour development than in the control group 
(tMDSC vs. IMC: 250.2 vs. 106.6; p < 0.01). The transfer of IMC had no significant 
effect as compared to untreated mice (relative size day 8: 249%; FRI: 98.5).  
 
3.2.4 S100A9+ cells dominate the infiltrative tumour margin 
Ex vivo histology confirmed the in vivo imaging results and revealed a strongly 




Figure 15: Immunohistochemistry for S100A9 in tumour tissue from mice that received tMDSC or 
IMC 
After transfer of tumour-primed MDSC, tumour tissue exhibits a higher density of S100A9-positive 
(red/brown) monocytic cells as compared to the tissue of mice that received naïve monocytic cells from 
healthy control animals. In both cases, S100A9-positive cells preferentially colonise the tumour periphery. 
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3.2.6 The source of S100A8/A9 in the tumour microenvironment are 
CD11b+ monocytes 
 
 Tissue culture supernatant Tissue culture cell lysates Resected tumor lysates 
Cell line 4T1 67NR 4T1 67NR 4T1 67NR 
S100A8/A9 
(ng/ml) 
0 0 0 0 86,897 1,927 
SD na na na na 50,044 1,348 
Table 1: S100A9 ELISA results 
 
ELISA of both, tissue culture supernatant and cell lysates of the different murine 
breast cancer cells was negative for S100A8/A9 protein expression while resected 
tumour samples, comprising tumour cells and the immune cell infiltrate, showed high 
S100A8/A9 levels. 4T1 tumour samples exhibited significantly higher protein levels 
than 67NR samples.  
To specifically control for expression of S100A9 by tumour cells in vivo, FACS 
analysis of resected tumour tissue was performed. Tumour samples from 4T1 or 
67NR regularly comprised less than 0.1% S100A9+ cells of other than monocytic 
(CD11b+) origin (Fig. 18), screening out the presence of S100A9+ tumour cells. 
In summary, tumour cells did not exhibit S100A9 protein expression in vitro or in vivo; 
the S100A9 expression as reflected by specific imaging is virtually exclusively 
indicative of tumour-associated monocyte/macrophage activity. 
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3.2.8 S100A9 imaging predicts local tumour growth and correlates with 
tumour type 
 
Figure 16: Correlation of S100A9-signal in primary tumour tissue and consecutive tumour growth. 
Mice, implanted with 4T1 tumours subcutaneously over the flank have been followed after aS100A9-
Cy5.5 driven FRI. Imaging was performed at a tumour size of 5 mm, 24 h after tracer application. The 
growth of the tumour was followed over a period of ten days and correlated with the initial imaging signal 
(C; n=11). Tumour-lesions with an initially high S100A9 signal presented with a strong infiltrate of 
S100A9+ cells in subsequent immunohistochemistry (B). Exemplary early imaging for low and high 
S100A9 in vivo imaging signal in A. 
 
The development of 4T1 tumours was assessed longitudinally over ten days, following 
imaging at an early stage of tumour development (tumour size < 5 mm).  
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A higher aS100A9-Cy5.5 signal in early FRI and the confirmatory detection of an 
increased presence of S100A9+ cells upon tumour resection was found in fast 
growing tumour lesions as compared to lesions with slower development and only 
mild aS100A9-accumulation. The S100A9 signal strongly correlated with the 
consecutive individual tumour growth (R² = 0.86; p < 0.0001, n = 11).  
 
 
Figure 17: S100A9-specific FRI in mice bearing 4T1 or 67NR tumours. 
4T1 tumour lesions (upper panel; n=10) accumulated significantly more S100A9+ monocytes as 
compared to 67NR tumour lesions (n=10; immunohistochemistry for S100A9 shown as inserts, 
representative FACS analysis on right panels). The in vivo imaging allowed for differentiation of tumour 
lesions according to the local S100A8/A9 release in correlation with the malignant potential (4T1 > 
67NR); for visual appreciation of S100A9-distribution in the 67NR model, the scaling of the fluorescence 
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signal had to be adapted and the lower threshold had to be reduced by a factor of three (normal images: 
1,500 – 2,500 AU; insert 500 – 1500 AU). Quantification is shown in the lower panel with *=p<0.05 and 
**=p<0.01. 
 
Targeted S100A9 imaging revealed significant differences between the two tumour 
entities with 4T1 tumours exhibiting the highest aS100A9-accumulation (FRI signal 
427.3 AU), and 67NR (250.8 AU). The ex vivo analysis of the tumour immune cell 
infiltrate revealed the presence of CD11b+ cells in all tumours, with the amount of 
S100A9+ cells among the immune cell infiltrate confirming the in vivo imaging (4T1: 
8.7% of total cell infiltrate; 67NR: 1.2%) and reflecting the specific grade of 
malignancy.  
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3.3 Discussion 
Tumour-associated immune cells are critical for the development of malignant 
disease. Numerous studies illustrated immune cells to be supportive of tumour 
development and spread on the one hand and the interference with the anti-tumour 
immune response on the other (90). Tumour immunotherapy, the strategy to inhibit 
the induction of tumour-promoting immune cells and consecutively increase the host 
ability to overcome the suppression of an effective anti-tumour immune response has 
been hailed a turning point in cancer therapy (4). Striking results have been reported 
in patients with advanced, even metastatic disease including lung, renal, prostate and 
breast cancer (91). Still, response varies largely among the selected patients and 
surrogate markers as to which patient might benefit from the treatment are largely 
elusive (92, 93). This specifically precludes monitoring of immunomodulatory cancer 
therapy as reliable diagnostic approaches for the determination of the biological 
activity within the tumour microenvironment are still missing. For both, clinical and 
preclinical applications, a method for sensitive monitoring of immune cell activity in 
malignant disease would be highly desirable. In clinical settings, it would enable 
patient stratification on the basis of tumour-mediated and -associated inflammation 
while in preclinical settings it would facilitate further research in tumour biology.  
With the technique, presented here, a potential way to address tumour-associated 
inflammation is established. I used a fluorescent-labelled antibody to target and 
visualise the protein heterodimer S100A8/A9, reflective of local monocyte activation. 
In a direct comparison of an equally sized, unspecific IgG, the S100A9-specific 
antibody showed a distinct distribution in selected tumour areas only (Fig. 14) and an 
overall higher signal intensity, reflecting the target-specific signal component as 
compared to perfusion/unspecific signal components only (Fig. 13). In S100A9 knock 
out mice, no specific signal could be induced (Fig 13). 
To further specify the source of S100A8/A9 in the tumour microenvironment and 
assess the sensitivity of S100A9 imaging for changes of the cellular composition of 
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the tumour microenvironment, I modulated in tumour-bearing mice the burden with 
tumour-primed MDSC. A higher level of MDSC led to an accelerated tumour-growth 
and was accompanied by a stronger infiltration of the tumour lesion by S100A8/A9+ 
monocytes (Fig. 15 + 16). This was reflected by a higher in vivo imaging signal (Fig. 
15) as compared to control mice. Tumour cells did not exhibit S100A8/A9 expression 
or release (Table 1).  
The abundance of S100A9+ monocytes in the tumour reflected by a high local 
S100A9 imaging signal correlated with the subsequent tumour development (Fig. 17). 
I could show an accumulation of the specific antibody in tumour lesions to be 
associated with a local increase in S100A8/A9+ monocytes. The tumour cells could 
be excluded as a source of local S100A8/A9.  
Taken together, local concentrations of S100A8/A9, as depicted by specific OI can 
serve as a marker for local monocyte activity in tumour-associated inflammation. This 
tumour-driven immune cell activity can be an indicator of the tumour ability to 
establish a supportive environment. 
  
3.3.1 Alternative cell tracking approaches 
Within cell tracking studies, featuring either iron oxide mediated MRI (94, 95) or 
radionuclide imaging e.g. using 64Cu liposome labels for PET (96), the abundance of 
macrophages and other phagocytes in the tumour microenvironment could already be 
shown. Within this study, we present an approach for visualisation of monocyte 
activity beyond sheer abundance in the primary tumour. With tumour-associated 
monocytes being discussed as prognostic indicator for tumour development (90, 97), 
this technique could provide valuable information on on-going tumour/immune cell 
crosstalk. 
S100A8/A9 has been shown to mediate the crosstalk between tumour cells and 
monocytes, macrophages and MDSCs (37, 43, 98). Local release closely reflects the 
monocyte/phagocyte activity (50), qualifying S100A8/A9 as an imaging target for 
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monitoring of tumour-associated inflammation. Within this study, this has been 
achieved by following the principle, established for visualisation of local monocyte 
activity in inflammatory processes (79). 
 
3.3.2 Correlation of S100A9 release and tumour development 
We now utilized this approach to address crucial components of the inflammatory 
tumour microenvironment using S100A9 as a marker for the activity of tumour-
associated monocytes. 
Although endogenous S100A9-expression has been proposed for several human 
tumour types (60, 99, 100) based on elevated systemic levels (99) and upregulation 
on the RNA-level, expression on the protein level has not been well documented. The 
systemic levels, reported in human cancer patients and observed in tumour-bearing 
animals are in this context also likely to represent activated monocytes. Although 
further evaluation of this hypothesis will be necessary, we could safely prove that 
none of the tumour cell lines we used for this study shows measurable S100A9-
release and thus, in these experimental tumour models, measured signals were 
mediated by tumour-invading monocytes. 
The rabIgG-Cy5.5 mediated, unspecific background signal can be attributed to local 
hyperaemia and binding of the IgG to Fcγ-receptor (FcγR), expressed on resident and 
invading immune cells (101) as well as e.g. endothelial cells (102). FcγR expression 
can equally effect on both, rabIgG and aS100A9-Cy5.5 accumulation and increase 
immune cell infiltration via immune complex formation (103). Both imaging signals are 
also influenced by the in vivo distribution kinetics of full length IgG – a slow clearance 
via the hepatic route, slow extravasation and evenly slow wash out, even in the 
absence of the target, leading to a high unspecific background signal, especially at 
early time points, up to 24 h after tracer administration. The superiority of aS100A9-
Cy5.5 over the unspecific isotype control has been extensively documented (79). In 
histology, we could detect S100A9 in colocalisation with immune cells of monocytic 
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heritage (TAM and MDSC), indicating a mutual relationship as recently suggested 
(59). Specific sites of monocyte-activity could be identified in vivo using S100A9-
driven FMT and confirmed by immunohistochemistry.  
It is well established that monocytes, recruited to the tumour, support local tumour 
growth and invasion (37, 50, 85, 104).  In vivo imaging of S100A9 expression allowed 
for stratification of tumour lesions according to the activity of tumour-associated 
monocytes. An established supportive microenvironment, reflected by a high S100A9 
in vivo imaging signal, favours the consecutive tumour growth as suggested by our 
results and may be interpreted as a novel indicator of reduced prognosis. 
 
3.3.3 Underlying/associated cellular events  
Monocytes have also been reported to support the first steps towards distant 
metastasis at primary tumour level (105, 106). In a murine model of graded 
malignancy (83), the different activity of tumour-associated monocytes, potentially 
supporting the systemic shed of cells from the primary tumour was reflected by 
S100A9 imaging. 
We artificially increased the number of tumour-primed MDSC in tumour-bearing 
animals. In tumour lesions of identical size, the transfer of tumour-educated splenic 
monocytes including MDSC resulted in an increased recruitment of S100A9+ cells to 
the tumour and significantly higher S100A9-mediated fluorescence in the tumour and 
stimulated a more aggressive tumour development in accordance with recent data 
(37, 85). An increase in naive monocytes however had virtually no effect on the 
activity of tumour-associated immune cells as reflected by S100A9 imaging and 
tumour growth. 
Our findings support reports about the crucial importance of tumour-associated 
monocytes – including MDSC – for tumour development and fit with reports on them 
mutually promoting their respective activity and accumulation in the tumour (9, 30). 
We could demonstrate that S100A8/A9 expression as measured by in vivo imaging 
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reflects TAM and MDSC abundance and the malignant development in individual 
tumours and may thus function as a surrogate marker for the tumour’s ability to recruit 
and activate immune cells to induce a supportive microenvironment. 
Future studies will have to elucidate the relevance of S100A9 expression in the 
context of other tumour models and the potential for S100A8/A9 to serve as a marker 
for response to immunomodulatory therapy. 
 
3.3.4 Implication for tumour staging and imaging 
OI of S100A9 allows for estimation of TAM/MDSC-activity in tumours and thus 
enables stratification of tumour lesions with regard to local tumour-host-interactions 
and the potential development. For basic research, this technique will offer the 
opportunity to study the role of TAMs and MDSC in malignant progression in more 
detail. With regard to clinical cancer research, the importance of tumour-associated 
immune cells as promoters of malignant progression and thus as potential targets for 
diagnostics and therapy is emphasized and a potential route for grading tumours 
according to tumour-associated inflammation is suggested. 
The study is however limited to the immediate tumour microenvironment, due to the 
methodological properties of OI. It does not allow for evaluation of potential systemic 
effects of the tumour such as interaction with the monocyte depots in bone marrow 
and spleen or the influence on potential target sites of metastasis. 
To assess the importance of tumour-immune interaction in the process of metastasis 
and gain insight into the role of immune cells in premetastatic tissue priming, the 
established imaging approach needs to be adapted for whole body and deep tissue 
imaging. 
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4 Establishment of a S100A9-specific SPECT tracer 
While OI is limited to superficial applications, radionuclide-driven imaging is virtually 
not limited by the mass of the examination sample. Retaining a sensitivity, 
comparable to or even superior over the sensitivity of OI, SPECT and PET qualify as 
systemic molecular imaging methods. As the basis for the aS100A9 tracer is a full-
length IgG with consecutively long tissue and blood pool half-life, 111In was chosen as 
a radioactive label. The half-life of 111In allows for safe detection up to 48 or even 72 
hours after tracer application (details on p 24).  
 
The aim of this work was to develop a S100A8/A9-targeted SPECT tracer for 
systemic visualisation and measurement of S100A8/A9 release, using an 111In-
labelled antibody. The tracer was assessed with respect to stability under 
physiological conditions. In addition, the tracer was applied in vivo for biodistribution 
and initially tested in a model of local inflammation that has previously been 
characterised for S100A8/A9 expression in the area of inflammation. 
 
4.1 Material and Methods 
4.1.1 SPECT tracer for S100A8/A9 
The protocol for labelling antibodies for SPECT imaging has been adapted from the 
protocol, established by Cooper et al (107). 
Briefly, the full length polyclonal antibody (1-2 mg/mL), addressing the S100A9 
subunit of the S100A8/A9 heterodimer, which has been used in all prior optical 
imaging studies (79, 82), was incubated with 50 mM EDTA in 0.1 M ammonium 
acetate for 30 min at room temperature for chelation of metal contaminations, 
subsequently purified and transferred to 0.1 M HEPES buffer, pH 8.5, using spin 
columns (molecular weight cut-off 30,000 kD; GE Healthcare UK Ltd, UK). Repetitive 
purification runs were performed until the antibody solution was regarded purified; at 
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least 30 mL HEPES buffer were used for the buffer exchange on spin columns of 1 
mL volume. The concentration of the antibody solution after purification was 
determined using a Nanodrop and the molar content was calculated (on average in 
the range of 0.005 – 0.008 mM/mL).  
A sufficient amount of the chelator SCN-Bz-DTPA (chemical formula 
C22H28N4O10S•3HCl, MW 649.9 g/Mol; Macrocyclics, Ltd., USA) was freshly dissolved 
in pure ethanol. On average, 1 µg chelator was dissolved in 100 µl ethanol to produce 
a solution of 0.015 mM concentration. 
 
 
Figure 18: Chemical structure of the chelator SCN-Bz-DTPA 
 
The purified antibody in HEPES buffer was incubated with a 20-fold molar excess of 
the chelator (on average around 80 µl chelator solution), at 4°C over night. The 
compound was thereafter purified from unconjugated precursors by ultrafiltration and 
resuspended in 0.1 M ammonium acetate, pH 6. The purity was determined by 
measuring the flow-through of the spin column for presence of light-absorbing 
chelator on a Nanodrop. The product was regarded sufficiently clean of unbound 
precursors when the measurement on the Nanodrop was 0 (no absorption).  
 
The conjugated product – aS100A9-DTPA – was kept at 4°C until further use. 
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For in vivo imaging, the required volume (1mg in 1mL) of the labelled compound was 
incubated with 150 MBq 111In chloride (specific activity 1.85 GBq/g In; Guy’s Hospital 
Radiopharmacy, London, UK) for 1 h at room temperature and subsequently purified 
from free 111In and transferred to PBS using a PD-10 desalting column (GE 
Healthcare UK Ltd, UK). The purity of the labelled compound was assessed using 
HPLC.  
111In-labelled aS100A9-DTPA (111In-aS100A9) was injected in amounts, 
corresponding to around 10 MBq per animal.  
 
As a control for unspecific label distribution due to perfusion and Fcγ receptor binding, 
a rabbit-derived IgG of irrelevant specificity in mice was labelled in an analogous 
manner (111In-rabIgG). The antibody has been raised in rabbits of identical origin as 
the aS100A9 in response to goat serum. 
 
4.1.2 In vitro stability assay 
To assess the stability of the antibody-chelator complex and the potential of the 
chelator to retain the radioactive label under physiological conditions, samples of the 
tracer were labelled with 111In and incubated in mouse serum (SIGMA Aldrich) at 37°C 
for 24 or 48 h. Before incubation as well as after this time, samples were analysed 
using HPLC. Retention of the radioactive label and structural integrity were 
determined with the HPLC retention time of the compound before incubation as a 
reference.   
 
4.1.3 In vivo biodistribution in healthy controls and a murine model of 
local inflammation  
For evaluation of the in vivo distribution under normal, physiological circumstances as 
a reference for the distribution under pathological conditions, the tracer was initially 
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administered to healthy wild type mice. Healthy female Balb/c mice, aged 8 weeks, 
were purchased from commercial suppliers (Charles River, UK) and kept for at least 
ten days after delivery to allow for sufficient rest after the transport. 24 hours before 
SPECT/CT scanning, the mice received 10 MBq 111In-aS100A9 intravenously via the 
tail vein. The tracer distribution was determined in vivo using SPECT/CT (see below) 
and ex vivo using gamma counting of isolated tissue samples, immediately after 
imaging. 
 
Irritant contact dermatitis (ICD) was established for studying local inflammation and 
innate immunity more than two decades ago (108-110).  
Following these protocols, ICD was induced in female Balb/c mice (age 8 weeks) by 
application of 1% croton oil in olive oil-acetone (1:4) to the dorsal surface of the right 
ear of mice for 24 h, while the left ear served as internal control. Imaging was 
performed at 24 and 48 hours after tracer application, corresponding to 48 and 72 h 
after croton oil treatment, respectively. Subsequently, mice were sacrificed and ears 
were snap-frozen in liquid nitrogen and transferred to immunohistochemistry. 
The swelling of the affected, croton oil-treated ear can serve as a clinical marker of 
inflammation and correlates with established markers of inflammation. The release of 
S100A8/A9 has been characterized earlier to peak between 24 and 48 h after croton 
oil-treatment and specific S100A9-imaging in this model has been demonstrated 
earlier to safely reflect the inflammation activity (79). 
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Figure 19: Kinetics and experimental design for irritant contact dermatitis 
Kinetics of ear swelling as clinical sign of cutaneous inflammation and influx of S100A9+ cells into the 
inflamed ear as determined by immunohistochemistry. Tracer was injected 24 h after induction of 
inflammation (T) and 24 h prior to in vivo imaging (S). 
Note that a significant ear swelling develops slower than infiltration of the site of inflammation with 
S100A9+ cells. The first cells, being activated in the course of local inflammation express high levels of 
S100A8/A9 and lead to further vascular leakage and immune cell accumulation and activation, resulting 
in full clinical manifestation of inflammation including the measurable ear swelling. At the time of peaking 
clinical inflammation, cells, representative of the acute phase of inflammation already started to 
differentiate into macrophages without S100A8/A9 expression.  
 
All experimental in vivo procedures were covered by the respective project licences 
70.7019, 70.7238, 70.7410, issued by the UK Home Office according to the Animals 
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Scientific Procedures Welfare Act. All personnel, involved in the in vivo experiments 
has been trained according to the King’s College London regulations and obtained a 




4.2 The preclinical SPECT/CT system 
 
All in vivo imaging experiments were conducted on a dedicated small animal SPECT 
system (NanoSPECT/CT; Mediso Medical Imaging Systems, Hungary). 
The scanner was calibrated for detection of 111In-emitted β-radiation.  
For imaging, a multi-pinhole collimator was installed, featuring 16 pinholes and a 
theoretical spatial resolution of 0.85 mm. The sensitivity, given by the manufacturer, 
was 7.500 cps/MBq. The system comprised a specific, heated mouse bed, which 
allowed for monitoring of body temperature and breathing rate of the animal during 
the examination. The injected dose per animal was measured and recorded before 
injection. Injected doses were kept consistent and the average dose, injected was 
around 10.0 MBq to ensure a reasonable image quality.  Tracers were applied 
intravenously into the tail vein 24 h before in vivo imaging.  
 
The imaging protocol comprised an orientating scout x-ray scan of the whole mouse 
bed for planning of the examination. On this scout image, the field of view for CT and 
consecutive SPECT scan was outlined. The maximum field of view, enabled by the 
specific mouse imaging collimators was 30 x 300 mm. 
On average, the field of view for whole body mouse scans in this study was 30 x 110 
mm and chosen carefully to cover the whole animal. CT scans were performed as 
helical scans with 240 projections. Average scan time for the CT was around 10 
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minutes. The SPECT scan was performed for the identical field of view with one 
minute frame times and an average of 50 frames per animal. 
For CT and SPECT scan together, the average scan time for a whole body mouse 
scan was around 60 minutes. For the duration of the scan, mice were kept under 
Isoflurane inhalation anaesthesia (2% Isoflurane in air) on the heated dedicated 
mouse bed. Immediately after scanning, mice were either culled for tissue collection 
or returned to dedicated caging in shielded areas.  
 
Imaging data were iteratively reconstructed and analysed using the in built VivoQuant 
Software (inviCRO, USA) and presented as percentage of the injected dose (%ID), 
based on the mean radioactivity within the ROI, normalised for the volume of the 
selected ROI.  
For individual organ analysis, 3D ROIs were drawn on the anatomic CT images. For 
lung examination, a ROI was placed centrally over the whole lung area, analysing 
right and left lung separately and therefore excluding the mediastinum and heart, 
representative of the blood pool. For spleen signal analysis, the spleen was identified 
on coronal and axial CT images and an elliptic ROI was placed in the central organ 
compartment, carefully excluding any neighbouring tissues such as liver and kidneys. 
The ROI size was identical for all parallel experiments. From parallel experiments, 
mean values and standard deviation were calculated for %ID. After in vivo imaging, 
mice were either kept for longitudinal follow up examinations or sacrificed for tissue 
collection for histology and FACS. 
 
4.2.1 Biodistribution in healthy controls 
On the in vivo SPECT scans, lungs, heart, liver and spleen were individually assessed 
as described earlier. ROI values of the organs, normalised for the ROI size, were put 
in relation to the overall body activity, resulting in a comparable relative tracer dose 
per organ. 
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After scanning according to the aforementioned protocol, mice were immediately 
culled. The body weight and the radioactivity, contained in the whole mouse carcass, 
were determined. Selected tissues including blood samples were collected, separately 
weighed and referred to gamma counting for measurement of the specific 
radioactivity. From all animals, lungs, heart, liver, spleen, intestine, bone 
(representative sample: spine segment) and a blood sample (lancet; 20 µl) were 
collected. 
From the sample activity, the organ weight and a dilution row of standardised 
amounts of the injected tracer, examined in parallel, the relative injected dose per 
gram tissue could be calculated as validation measure for the in vivo imaging as 
follows: 
%ID/g =ActivityOrgan [CPS] x Gradientdilution row / ActivityInjection [MBq] x100 / organ weight 
[g] 
 
4.2.2 In vivo imaging in local inflammation 
24 hours after tracer injection, 48 hours after croton oil-treatment and induction of 
local inflammation, mice underwent SPECT/CT scanning according to the 
aforementioned protocol. 
For image analysis, 3D ROIs were drawn to completely cover the right (affected) or 
left (control) ear, respectively. ROI sizes were identical for all parallel experiments. 
The in vivo tracer distribution was presented as %ID, calculated as follows: 
%ID = ActivityROI [CPS] / ActivityMouse [CPS] x 100 
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4.3 Results 
4.3.1 Production of the S100A9-specific tracer  
4.3.1.1 Conjugation and labelling of a polyclonal antibody against 
S100A9 
 
The polyclonal antibody, targeted on the S100A9 subunit of the S100A8/A9 
heterodimer was generated by Prof Johannes Roth’s laboratory at the Institute of 
Immunology, University of Münster, Germany and characterised earlier (86, 111). The 
antibody was conjugated with a chelator (DTPA), following established standard 
protocols (107), adapted for this specific antibody. 
After conjugation, the antibody-chelator construct was examined using HPLC and 
compared to naïve antibody to verify purity from unbound precursors. 
 
 
Figure 20: HPLC analysis oft he antibody-chelator compound 
Minimal impurities, detectable via size exclusion HPLC before purification (upper panel), vanished 
completely after purification (lower panel). 
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The purified construct was then incubated with 111In for labelling. The labelled 
construct was again examined using HPLC before and after incubation under 
physiological conditions for 24 and 48 hours. 
 
4.3.1.2 Stability of the labelled compound 
 
No significant impurities could be found in the construct preparations. The chelator 
retains the activity safely for over 48 hours and the HPLC curves do not indicate 
instability in the antibody-chelator construct for the observation period. An identical 
shape of the HPLC curves over time suggests that the compound is stable under 
physiological conditions in vitro. 
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Figure 21: Stability of the compound under physiological conditions 
The HPLC analysis of labelled 111In-aS100A9 proves stability and label retention of the complex over up 
to 48 hours under physiological conditions in vitro.  
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4.3.2 In vivo testing in healthy animals 
S100A8/A9 are released under physiological conditions at low levels in the context of 
multiple processes such as growth and healing as well as during inflammation and 
infection. The baseline level, found in serum and local tissues, increases strongly 
during inflammation due to activation of monocytes. 
In healthy animals, no focal S100A8/A9 release should be detectable; a moderate 
background level should be present. 
Application of 111In-aS100A9 in healthy mice without foci of infection or inflammation 
resulted in an evenly low distribution of the probe in the mouse body as depicted by 
SPECT. Relatively high activity could be detected in the liver, due to the physiological 
route of elimination of larger proteins from the blood pool. 
No specific accumulation of the tracer could be detected. 
Ex vivo analysis of the tracer uptake and retention by gamma counting confirmed the 
in vivo imaging results. 
 
 
Figure 22: Biodistribution of 111In-aS100A9 in healthy controls 
Relative activity per gram tissue in selected body compartments, 24 h after application of 111In-aS100A9 
in healthy animals (n=5; mean +/- SD).  
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4.3.3 In vivo testing in a model of local inflammation 
To assess the specificity of 111In-aS100A9 for activated immune cells, we used a 
model of local inflammation, well characterised for strong, local S100A8/A9 release. 
By application of the toxic dermal irritant croton oil to the dorsal surface of the mouse 
ear, an acute dermatitis is elicited. Within hours, a strong infiltrate of innate immune 
cells including activated monocytes locally releases S100A8/A9. The model moreover 
offers an ideal internal control in the form of the unaffected, healthy ear. 
To control for tracer distribution, related to increased perfusion and vessel 
permeability in the area of inflammation, an antibody of irrelevant specificity in mice 
was used (rabIgG). 
Animal with local inflammation received 111In-aS100A9 or 111In-rabIgG 24 h before 
SPECT imaging. 
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Figure 23: SPECT imaging in local inflammation 
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SPECT imaging 24 h after iv injection of about 10 MBq 111In-aS100A9 (left) or 111In-rabIgG (right). 
Exemplary images of a whole mouse and representative axial images of the region of inflammation, the 
thorax and mediastinum and the liver. 
 
The accumulation of 111In-aS100A9 in the area of inflammation is significantly higher 
than the accumulation of 111In-rabIgG. The distribution in non-target organs, 
unaffected by inflammation, was virtually identical for both contrast agents. 
Ex vivo biodistribution confirmed the in vivo imaging results.  
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Figure 24: In vivo SPECT in local inflammation – data analysis 
The distribution of 111In-aS100A9 (dark grey) and 111In-rabIgG (light grey) was virtually identical in non-
target organs. In the area of inflammation (Right Ear), the accumulation of 111In-aS100A9 was 
significantly higher than the accumulation of 111In-rabIgG, representing hyperaemia (n=8/4; ***=p<0.001). 
Differences between the two tracers in the healthy control ear were not significant. 
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Figure 25: Ex vivo biodistribution in local inflammation. 
Immediately after imaging, resected organs were weighed and the remaining activity was measured. The 
ex vivo biodistribution study confirms the in vivo imaging results with a strong accumulation of aS100A9 
(dark grey) in the area of inflammation. In non-target organs, such as the control ear, heart and liver, 
accumulation of the specific tracer and rabIgG (light grey) as unspecific control was virtually identical. 
Notable differences could be detected in lungs and spleen, potentially representative of systemic 
activation of innate immune cells. Both tracers exhibited a high activity in the collected blood samples, 
probably due to the long circulation time, slow elimination and extravasation. 
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4.4 Discussion 
4.4.1 Review of results 
From a polyclonal antibody, targeting the S100A9 subunit of the S100A8/A9 
heterodimer, the S100A9-specific tracer aS100A9-DTPA could be constructed via 
established conjugation chemistry. After labelling with 111In, the tracer retained – 
according to HPLC analyses – structural integrity and the radiolabel for over 48 h 
under physiological conditions in vitro (Fig. 22) and was therefore regarded suitable 
for in vivo application. 
A signal, detected by 111In-guided in vivo SPECT imaging would therefore most likely 
represent the specific tracer, not dissociated tracer components, which would 
potentially lose target specificity and potentially fall below the renal elimination 
threshold. Over the examination period, kidneys and especially the urine bladder were 
virtually void of radioactivity (Fig. 25), which would have been indicative of dissociated 
tracer components. 
In the earlier studies, using fluorescent-labelled antibody constructs, a fluorescent 
signal could be detected in the bladder 24 h after tracer application. Comparing the 
studies, this must be attributed to impurities (unbound dye) in the fluorescent tracer 
solution while the conjugated antibody has been purified with more accuracy using 
HPLC (Fig. 21).  
The antibody, used as a basis for both, the fluorescent tracer as well as the SPECT 
tracer has been extensively tested for specificity and binding characteristics, before 
this study was conceived (86, 111).  
Having used only relatively small labels – a cyanine dye for the fluorescence imaging 
experiments and a DTPA variant for the SPECT imaging – the probability that 
labelling would fundamentally change the binding characteristics such as affinity of 
the antibody was quite low. We therefore abstained from testing the labelled 
compounds with regards to their binding affinity and concentrated on the in vivo 
performance including specificity of the tracer accumulation. Several factors 
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hampered an in vivo blocking study for further validation of the in vivo imaging data: 
S100A8/A9 exhibits a high and rapid turnover which would require repetitive 
administration of unlabelled precursors to achieve an effective blocking of the target 
epitope. However, the availability of the antibody was limited and having shown the 
target specificity in knock out studies and the sensitivity for the imaging signal for 
changes in target expression, we abstained from escalating the specificity testing 
further.  
For estimation of perfusion effects due to increased permeability in the target region, 
a full length IgG of irrelevant specificity in mice was successfully conjugated, purified 
and labelled accordingly. This tracer is of similar size and allows the investigation of 
unspecific tracer distribution for direct comparison with the target-specific tracer.  
Examination of healthy animals after injection of the probes revealed a typical 
distribution pattern of antibody-sized molecules: For the whole observation period, 
remaining tracer could be detected in the blood pool, represented in vivo by the 
mediastinum/heart region. The retention in the blood pool even allowed for delineation 
of the carotid arteries and other big vessels. At later time points, the tracer 
accumulated in the liver and was slowly eliminated from there. No elevated uptake or 
retention in the kidneys or urine bladder could be observed, confirming virtually 
exclusive elimination via the hepatic/biliary pathway. 
In the model of local inflammation, the 111In-rabIgG scan revealed increased perfusion 
and enhanced vessel permeability in the area of inflammation as compared to the 
untreated control side. However, the accumulation of the S100A9-specific probe was 
significantly higher in the area of inflammation with – compared to the 111In-rabIgG 
scan – virtually identical background signal. The difference between the two, 
structurally nearly identical probes, confirms the specificity of aS100A9 for 
inflammation activity beyond secondary signs like hyperaemia and impairment of 
vessel integrity. 
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4.4.2 Characteristics of antibody-based probes 
Full length IgG antibodies usually weigh around 150 kDa and therefore exceed the 
upper limit for renal elimination, which is usually defined around 30 kDa. The result is 
a prolonged circulation time and slow elimination of unspecifically distributing tracer, 
constituting a potentially disturbing background signal for longitudinal studies with 
recurrent examinations. Moreover, the transit of large molecules from the blood pool 
through the vessel wall and potential further stromal tissue to finally reach a certain 
target structure can be hampered or at least be delayed. 
As a result, the optimal imaging time point for antibody-driven imaging approaches 
would normally not be earlier than 24 h after tracer application (112). This demands 
the use of isotopes with long half-life to guarantee enough activity at the time of 
imaging.  Smaller targeting molecules like antibody fragments of different size or even 
smaller Nano- and Affibodies have been tested to overcome this limitation. The serum 
half-life of Fab antibody fragments – about 50 – 55 kDa in size – has been shown to 
be reduced to 12 – 20 hours as compared to around one week for full length IgG (73). 
Smaller peptide structures like Nano- or Affibodies – usually smaller than 15 kDa – 
are eliminated even faster with a serum half-life less than one hour (113, 114). These 
tracer substances would allow for the use of isotopes with shorter half-life and 
therefore prospectively unlock the translational potential of target-specific imaging. 
Moreover, this would enable more frequent, repeated scanning without a signal 
overhang from previous examinations. The shorter serum half-life of smaller 
molecules does however usually result in a less pronounced accumulation in the 
target area, as the constant washout of the tracer is higher than it is for bigger 
molecules. It would in any case be necessary to determine the optimal imaging time 
point and consecutively appropriate radioisotope. 
While labelling of big molecules like intact IgG can be done following relatively easy 
protocols for random labelling of e.g. Cysteine functions and only a comparatively 
small fraction of the antibody will loose specificity and binding affinity due to label 
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overload or obstruction of the relevant binding site, the labelling of a small tracer 
molecule requires a more sophisticated approach. Chelator and/or dye are relatively 
small as compared to an intact IgG (chelator size: around 1 kDa) with only little 
chance that addition of such a small structure would influence the functionality of the 
antibody. For small molecules however, conjugation to a chelator or dye can 
fundamentally change the binding affinity and ability. Site-specific labelling 
approaches overcome this hurdle with specifically engineered sites for label 
attachment, added to the targeting moiety. This requires engineering and in the case 
of antibody fragments or comparable peptidic tracers it would require clonal   
expansion of the tracer.  
In summary, antibody-based probes are highly potent for preclinical research as they 
offer very high specificity and are easily adapted for imaging research. Direct 
correlation by using the identical antibody for in vivo imaging, FACS and microscopy 
moreover increases confidence in the reliability of research results. For translational 
purposes, practical reasons prompt the use of alternative targeting molecules with 
more favourable biodistribution patterns and the potential to use short-living isotopes.  
 
4.4.3 Potential alternative strategies for S100A9-imaging 
Despite the polyclonal antibody that has been used for this project as well as the prior 
work on optical imaging of inflammation and tumour-associated monocytes (79, 82), 
only very few approaches, exploring S100A8/A9 for imaging, have been published so 
far. In a recent study, the possibility to detect and measure S100A8/A9 using mass 
spectrometry has been demonstrated in isolated tissue samples (frozen biopsies) of 
wound healing (115). Although the technical process of sample preparation still strictly 
limits mass spectrometry to the analysis of tissue samples ex vivo, steps are being 
taken towards bringing mass spectrometry imaging towards in vivo application (116). 
It is unlikely that spectrometry will replace whole body in vivo imaging. It might, 
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though, contribute insight on target distribution on a cellular level and therefore add 
valuable concomitant information in combination assays. 
The lack of S100A9-targeted imaging studies can not be attributed to a lack of 
potential tracers as even aside from the antibody construct, I have been using for this 
and other studies, other S100A8/A9-binding molecules exist. 
Tasquinimod is a small molecule (0.4 kDa) that specifically binds and sequesters 
S100A9, inhibiting downstream signalling of the protein (117). Tasquinimod has been 
extensively tested in vivo and recently reached phase II clinical trials for the treatment 
of castration-resistant prostate cancer (118). Modification of the molecule to enable 
labelling for in vivo imaging would result in a potent, very small and therefore probably 
rapidly distributing imaging agent. However, due to the size of Tasquinimod, 
conventional labelling chemistry as used to generate aS100A9-DTPA would bear an 
enormous risk of interference with the binding function of the substance and site-
specific labelling approaches would have to be employed. A group of chemists from 
the European Institute of Molecular Imaging recently published a labelled variant of 
Tasquinimod as a potential alternative to antibody-based tracers (119). 
Alternative antibodies such as monoclonal murine or camel antibodies, the latter of 
significantly smaller size as compared to human and murine antibodies, are currently 
being generated and tested in the laboratories of Johannes Roth in Münster, 
Germany and Tony Ng/Kerry Chester, London, UK. It would be possible to isolate, 
from these monoclonal antibodies, small antibody fragments that could in theory 
combine the binding affinity and specificity of the original antibody with a more 
favourable biodistribution due to the reduced size. 
As at the moment, the polyclonal antibody I have used for OI of inflammation and 
primary tumour associated immune cell activity is the only established tracer for 
S100A9, the study on in vivo imaging of tumour-mediated immune remodelling, was 
also pursued using the aforementioned compound. In the future, small targeting 
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molecules and alternative antibodies/antibody fragments will surely be available and 
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5 Systemic S100A9 imaging to unravel tumour 
immune crosstalk 
In a syngeneic, orthotopic model of metastatic breast cancer, 111In-aS100A9-driven 
SPECT has been assessed for visualisation of tumour-mediated immune activity. 
Differences between tumour-bearing animals and healthy controls and high and low 
malignant tumours have been assessed, focussing on the spleen as the systemic 
monocyte depot and the lungs as target organs of metastasis. 
The underlying effects on immune cell abundance and activity were evaluated and the 
cellular environment in premetastatic tissue was examined. 
 
5.1 Material and Methods 
5.1.1 Murine model of metastatic breast cancer 
The murine (BALB/c) breast cancer cell lines 4T1.2 and 67NR represent an 
established model system of graded malignancy with 4T1.2 tumours rapidly inducing 
distant metastasis in lung and bone, while 67NR tumours grow only locally (83). Both 
cell lines originate from a spontaneous breast tumour, isolated from a Balb/c mouse in 
Frank Miller’s laboratory at the Kormanos Cancer Center.  
Tumour cells were cultivated under standard tissue culture conditions (37°C; 5% CO2 
in air; constant humidity) in Dulbecco’s Modified Eagle Medium (DMEM, Sigma, 
Dorset, UK) complemented with 10% foetal bovine calf serum (FBS), 
penicillin/streptomycin and and 2mML-glutamine.  
At the day of tumour inoculation, cells were harvested from tissue culture flasks by 
trypsination, counted and kept in phosphate buffered saline (PBS) on ice for no longer 
than one hour before implantation. 1x106 cells were implanted orthotopically into the 
mammary fat pad of 8 week-old female BALB/c mice obtained from Charles River, 
UK.  
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Mice were kept under controlled conditions in the Division of Imaging Sciences BSU 
and tumour growth was measured daily. Temperature and day/night rhythm was 
constant and identical for all animals. The cages were equipped with a special soft 
paper bedding to prevent superficial erosion or laceration of the growing tumour 
lesion. Water and chow were offered ad libitum. 
 
5.1.2 Cell labelling with viral constructs 
For easier identification of tumour cells in tissue cell suspensions for FACS analyses 
or fluorescence microscopy of tissue samples, the experiments were performed with 
tumour cells lines that were engineered to stably express a membrane associated red 
fluorescent protein (mCherry). The viral vector for the protein was expanded in E.coli 
and isolated and purified using commercially available preparation kits (miniPREP, 
GE Healthcare UK).  
Naive tumour cell lines and mCherry-positive cell lines did not differ regarding in vitro 
or in vivo growth or malignant behaviour including the establishment of distant 
metastasis. 
 
5.2 Study Design 
 
Purpose Specificity Immunological Grading Regulation Predictive 
Potential 
 n  12 9 15 25 9 6 15 
Model 4T1.2 Controls 67NR 4T1.2 4T1.2 4T1.2 
(mCherry+) 




Tracer aS100A9 / rabIgG aS100A9 
Imaging  d10 d10 
 d20 
 
FACS  Immune cell infiltrate and function in lungs, spleen, blood, tumour tissue 
 mCherry+ metastasis 
Table 2: Experimental procedures and study design 
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Figure 26: Graphic display of the in vivo experiments. 
For all in vivo experiments, animals underwent tumour inoculation into the mammary fat pad at d 0. 
Depending on the experimental purpose, imaging was conducted not earlier than d 10 after tumour 
implantation and further analysis of tissue samples for either metastatic burden or activation and 
differentiation of immune cells (moncytes, NK cells, T cells) was conducted immediately after the imaging 
or up to 10 days later to assess the predictive value of S100A9 imaging. 
 
 
5.2.1 Systemic imaging in tumour-bearing animals 
 
At specific time points after tumour inoculation, tumour-bearing animals underwent 
S100A9 and rabIgG SPECT imaging as described before.  
Day ten after tumour inoculation was chosen as representative of an early phase of 
tumour development. Average tumour size at day ten was around 5 – 8 mm. No 
animal, examined at day ten after tumour induction, exhibited a detectable metastatic 
tumour spread. 
For assessment of late stage tumour effects, mice were examined at day 20 or later 
after tumour induction. Average tumour size at this time point was 10 mm. In some of 
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the animals, examined at this time point, manifest lung metastasis and enlargement of 
inguinal lymph nodes, indicative of tumour invasion, could be detected. 
Experiments were terminated and mice were culled before tumour lesions could grow 
beyond a volume of 1 mL. 
24 h prior to the respective imaging time point, mice received 111In-aS100A9 or 111In-
rabIgG in amounts, corresponding to 10 MBq activity intravenously via the tail vein. 
Imaging was carried out according to the aforementioned protocol for SPECT/CT 
imaging (p 62). 
After imaging, mice were either kept in designated, shielded areas for longitudinal 
examination or culled immediately for collection of tissue samples for further 
validation. 
 
5.2.2 Systemic S100A9 imaging under CCL2 blockade 
In vivo blocking of CCL2 was performed in analogy to established protocols (120): 
4T1.2 tumour-bearing mice received an intraperitoneal injection of 100 µg goat 
polyclonal anti-CCL2 antibody (R&D, Abingdon, UK) in 100 µl PBS every other day 
beginning on day 4 after tumour inoculation. Control mice were in parallel treated with 
100 µg normal goat polyclonal serum in 100 µl PBS. 
To control for the effect of CCL2 and further assess the role of the CCL2-CCR2 axis 
in promoting the release of S100A8/A9 from positive cells, monocytes and 
granulocytes of particular character (monocytes: 
CD11b+CD115+CCL2highCX3CR1low; granulocytes Gr1+CR2+CD115-) were 
isolated from spleen tissue of tumour-bearing mice by FACS, seeded into 96-well 
plates and treated with 50ng/ml recombinant mouse CCL2 (Invitrogen). After 48 h, the 
supernatant was collected and screened for S100A8 using ELISA (DuoSet, R&D 
systems) according to manufacturers’ instructions. Samples from 4T1.2 tumour-
bearing animals as well as 67NR tumour-bearing animals were examined. 
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5.2.3 Ex vivo validation studies and immunological function assays 
5.2.3.1 Characterisation of tumour cells for S100A8/A9 release 
To exclude the tumour cells as the primary source of S100A8/A9, responsible for in 
vivo SPECT signals, the release of S100A8/A9 by tumour cells of both, 4T1.2 and 
67NR cell lines, has been assessed. 
Using a S100A9-specific ELISA, established at the Institute of Immunology, University 
of Münster, Germany, cell culture supernatant of 4T1.2 and 67NR cultures and cell 
lysates of both cell lines have been screened for S100A9, as described in detail 
earlier (54).  
The cell culture supernatant was left at least three to five days on the growing cells to 
allow for a potential titre to build up in the supernatant. For cell lysates, samples of at 
least 1x106 cells were used, washed thoroughly after harvesting and lysed following 
standard protocols. 
Additionally, single cell suspensions from tumour tissue, resected from mice 10 days 
after tumour inoculation have been examined. The cells were dually stained for 
CD11b and S100A9 and screened for single and double positivity. 
 
5.2.3.2 Biodistribution studies and tissue collection for immunological 
studies 
Mouse organs were collected immediately after scanning at either day 10 or day 20 
after tumour inoculation, representative of early or late phases of malignant disease. 
The mouse carcass was weighed and the overall body activity was measured. 
Dissections were carried out under surgical conditions. From all animals, lungs, heart, 
liver, spleen, kidneys, intestine, bone (representative sample of spine) and a blood 
sample (20 µl in lancet capillary) were collected and separately weighed. The retained 
radioactivity was determined by gamma counting. For each organ, the relative dose 
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per gram tissue was calculated from the collected data and a dilution row of the 
injected tracer, examined in parallel. 
Representative tissue samples were at the same time separated for FACS or 
histology studies. 
Cell suspensions were prepared from the isolated organs for flow cytometry analyses 
and cell sorting as described below. Tissue for consecutive FACS analysis was 
immersed in ice-cold DMEM immediately after resection.  
Tissue samples for future histological examinations were embedded in optimum 
cutting temperature (OCT) compound and snap-frozen in liquid nitrogen-cooled 2-
Methylbutane, immediately after resection. 4-5 mm thick sections were cut using a 
Bright 5030 microtome cryostat (Bright Instruments, Cambridge, UK) and stored at -
80°C for further immunofluorescence staining and confocal microscopy analysis. 
 
5.2.3.3 Analysis of immune cell activity and function 
5.2.3.3.1 Reagents and antibodies 
 
Tissue culture consumables: Dulbecco’s modified eagle medium (DMEM), heat-
inactivated fetal bovine serum (FBS), Dulbecco’s phosphate buffered saline (DPBS) 
(all Gibco, UK), L-glutamine, Penicillin/Streptomycin (all GE Healthcare), 10x Trypsine 
and bovine serum albumin (BSA) (all PAA)  
Reagents for preparation of cell suspensions: Red blood cell lysis buffer, 2-
Methylbutane (all Sigma-Aldrich), Foxp3 staining kit, containing 
Fixation/Permeabilization concentrate, Fixation/Permeabilization diluent and 10x 
Permeabilization Wash Buffer (eBioscience), Live/Dead yellow (Life Technologies and 
Hoechst).  
A list of all antibodies that were used for this project can be found in table 3. 
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Hamster IgG 25-0031 1:100  eBioscience 
 Biotin OKT3 
Mouse 
IgG2a 
 1:200  eBioscience 
CD4 APC    1:100   
 FITC GK1.5 Rat IgG3b 100405 1:100  BioLegend 
CD5 Biotin 53-7.3 Rat IgG2a 13-0051 1:200  eBioscience 
CD8 Biotin 53-6.7 Rat IgG2a 13-0081 1:200  eBioscience 
CD11b V450 M1/70 Rat IgG2b 48-0112 1:100  eBioscience 
CD19 Biotin 1D3 Rat IgG2a 13-0193 1:200  eBioscience 
CD25 PE PC61.5 Rat IgG1 12-0251 1:100  eBioscience 
CD27 PE LG.7F9 Hamster IgG 12-0271 1:100  eBioscience 
CD49b PE-Cy7 DX5 Rat IgM 25-5971 1:100  eBioscience 
CD107 APC 1D4B Rat IgG2a 121613 1:100  BioLegend 
CD115 - 3-4A4 Rat IgG2b SC-02  1:10 Santa Cruz 
 Biotin AFS98 Rat IgG2a 130-101-913 1:20  MACS 
CCR2 - N-14 Goat IgG SC-31563  1:25 Santa Cruz 
Foxp3 V450 FJK-16s Rat IgG2a 48-5773 1:50  eBioscience 
Ly-6G Biotin 1A8 Rat IgG2a 130-101-884 1:20  MACS 
NK-p46 FITC 29A1.4.9 Rat IgG2a 130-102-300 1:50  MACS 
 V450 29A1.4 Rat IgG2a 48-3351-82 1:50  eBioscience 















Rat IgG Alexa488 - Goat IgG A11006  1:200 
Life 
Technologies 
Goat IgG Cy3 - Donkey IgG 705-165-147  1:200 
Jackson/Strate
ch 






  45-4317 1:200  eBioscience 
Table 3: Summary of antibodies, used in this study 
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5.2.3.3.2 FACS sorting for MDSC identification 
 
Samples from lungs, spleen and primary tumour tissue were screened for 
immunomodulatory MDSC and other sources of S100A8/A9, using FACS. 
The isolated organs were mashed immediately after resection and put through a 
Falcon cell strainer (100 µm mesh size; Fisher Scientific, UK), suspended in ice-cold 
DMEM, to create a single cell suspension. The coarse cell suspension was then 
incubated with ACK lysis buffer (Thermo Fisher Scientific, UK) for 5 minutes to get rid 
of red blood cells. After purification, the single cell suspensions were washed and 
resuspended in PBS. Per well of a 96 wells plate, 500,000 cells were seeded. All 
steps were carried out at room temperature. The cells were washed with 200 µl PBS 
and incubated with 50 µl Live/Dead yellow. After 20 min, cells were washed with 200 
µl PBS. Subsequently, 50 µl of the primary antibodies in MACS (1XPBS/1% 
FBS/2mM EDTA) were added per well and incubated for 20 min. The primary 
antibody mixture consisted of biotinylated lineage markers (CD3, CD5, CD8, CD19, 
CD115, Ter119, Ly6G) and directly conjugated NKp46 to identify NK cells, as well as 
directly conjugated CD4 and CD25 to distinguish Treg. See Table 3 for information on 
the antibodies that have been used. Thereafter, the cells were washed with 200 µl 
MACS and 50 µl of Streptavidin-PerCP-Cy5.5 in MACS were added, and again 
incubated for 20 min. Cells were washed with 200 µl MACS, followed by fixation and 
permeabilization with Fix/Perm for 30 min. Per well, 200 µl 1x Permeabilization wash 
buffer (Perm/Wash) were added to wash the cells. Next, cells were incubated for 45 
min with 50 µl Foxp3 or S100A9, diluted in Perm/Wash. The cells were washed twice 
with 200 µl Perm/Wash, once with 200 µl MACS and finally resuspended in 200 µl 
MACS. Samples were measured using the BD FortessaTM cell analyser and data were 
processed with FlowJo 8.7 (Tree Star Inc.). 
 
For identification of immunomodulatory MDSC, a specific gating strategy was applied 
during FACS analyses. The markers included Gr-1, CD115, CCR2 and CX3CR1. 
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Starting with gating to define live cells (Yellow Dead-), sorting for single-cell 
populations (FSC-A vs. FSC-H plot) was applied. Gates were set according to 
fluorescence-minus one (FMO) controls for Gr-1 and CD115, CCR2 and CX3CR1. 
FMO control for intracellular staining with S100A8/A9 in this and other cell 
populations. For detection of Tregs, a gating strategy including markers CD4, CD25 
and Foxp3, again with FMO, was applied. NK cells were identified according to 
negativity of other lineage markers (CD3, CD5, CD8, CD19, Ter119, CD115, Ly6G) 
and as NKp46+CD49b+; a FMO control was applied for staining with CD107 (LAMP1). 
 
 
Figure 27: FACS gating strategy for identification of MDSC 
Following selection of live, single cells via Life-dead staining and gating for FSC-A/H, CD115/Gr-1 double 
positive cells were gated and screened for CX3CR1 and CCR2. 
 
5.2.3.3.3 Marker panel for tumour immune remodelling 
In cell suspensions from lung tissue, harvested from tumour-bearing mice, the 
abundance and activity of Treg and NK cells was determined. 
Following production of single cell suspensions and the staining principle procedures 
as described earlier (p 81), the markers used for this specific purpose were CD25 and 
Foxp3 for identification of Treg and CD107 as activity marker of NK cells. 
Tissue samples were stained and sorted for all three markers in parallel to assess the 
association and presence of Treg and NK cells in the same tissue sample. 
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Figure 28: FACS gating strategy for identification of Treg (A) and NK cells (B). 
Following identification of live, single cells as described for the MDSC already, lineage markers for Treg 
or NK cells were applied to identify the respective cell populations in the examined tissue samples. 
 
5.2.3.3.4 Immunohistochemistry for validation of in vivo imaging 
From all organs, examined using in vivo imaging, tissue samples were processed for 
histology for direct, visual verification of in vivo imaging results. 
In particular, the spatial association of S100A8/A9 releasing cells, and 
Gr1+CD115+CCR2highCXCR1low monocytes/MDSCs was to be demonstrated. 
In this context, a protocol for simultaneous staining for S100A8/A9, CD115 and CCR2 
was established and executed on selected sectioned samples of lungs, spleen and 
primary tumour tissue of mice, bearing 4T1.2 or 67NR tumours. 
All tissue samples were embedded in optimum cutting temperature compound (OCT; 
Sakura Finetek Europe, The Netherlands) and snap-frozen in liquid nitrogen-cooled 2-
Methylbutane, immediately after resection from the animals. From these samples, 5 
µm thick sections were cut using a Bright 5030 microtome cryostat (Bright 
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Instruments, Cambridge, UK) and stored at -80°C for immunofluorescence staining 
and confocal microscopy analysis.  
At the time of staining, tissue was fixed in ice-cold neat acetone for 20 minutes. Slides 
were then labelled and a circle was drawn around each section using a hydrophobic 
pen (DAKO, Ely, UK) to minimise reagent use and to prevent accidental staining of 
adjacent sections.  
All incubation steps were carried out at room temperature and in the dark, unless 
stated otherwise. The sections were defrosted and rehydrated for 10 min with 200 µl 
PBS, followed by 20 min incubation with 200 µl 3.7% PFA. Afterwards, the sections 
were washed five times with 200 µl PBS and the samples were blocked using 200 µl 
blocking solution (PBS/1% FBS/1% BSA). After 30 min, the sections were washed 
five times with 200 µl PBS and incubated overnight with 100 µl CD115 and CCR2 in 
blocking solution at 4°C. Again, sections were washed eight times with 200 µl PBS 
and incubated with 100 µl DαG-Cy3 in blocking solution for 1 h. Afterwards, sections 
were washed five times with 200 µl PBS and 100 µl goat anti-rat-Alexa488 in blocking 
solution was added for 1 hour. Subsequently, the samples were washed five times 
with 200 µl PBS, incubated with 100 µl Fix/Perm for 30 min, and washed five times 
with 200 µl Perm/Wash. Subsequently, the sections were incubated for 2 hours with 
100 µl S100A8 in Perm/Wash, washed five times with 200 µl Perm/Wash and 
incubated for 1 hour with donkey anti-rabbit-Cy5 in Perm/Wash, before being washed 
five times with 200 µl PBS. Next, the sections were stained with 100 µl Hoechst for 20 
min, washed five times with 200 µl PBS and finally mounted.  
Images were acquired using the Carl Zeiss Laser Scanning Microscope 510 (LSM-
510) equipped with 405, 488, 543 and 633 nm lasers and using 20x and 40x multi 
immersion objectives and the 63x oil immersion objective. The software used to 
acquire images was Zen 2009 (Carl Zeiss, Welwyn Garden City, UK). 
Images were analysed using the ImageJ software (National Institute of Health). 
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5.3 Results 
5.3.1 Biodistribution in tumour-bearing animals 
Tumour-bearing animals were injected with 111In-aS100A9 24 hours prior to SPECT 
imaging. The examination was performed on established tumours, about 14 days after 
tumour induction. The average lesion size was 8 mm as determined by calliper 
measurement. 
After imaging, selected tissues were harvested for validation of in vivo imaging results 
by gamma counting and histology. 
A strong accumulation of the S100A9-specific probe could be observed in the primary 
tumour, confirming the OI results (Chapter 3). As compared to healthy control 
animals, an increased tracer accumulation could also be observed in spleen and 
lungs. The retention of the tracer in the liver was virtually unaltered. 
A high signal in the mediastinum/heart region hinted towards presence of the tracer in 
the blood pool and could not be verified ex vivo. In contrast, tracer accumulation in 
tumour, lungs, spleen and liver could be confirmed by gamma counting. 
111In-rabIgG signals in lungs and spleen did not significantly differ from signals in 
healthy controls; the retention in the tumour was significantly lower as compared to 
111In-aS100A9. 
 
	   95 
 
Figure 29: In vivo SPECT imaging in 4T1 tumour-bearing animals. 
Exemplary images of mice, 24 h after i.v. injection of 111In-aS100A9 or 111In-rabIgG. Tumours (4T1) were 
implanted in the mammary fat pad (n=12; n=6 per tracer)  
Differences in accumulation can be observed in lung tissue (0.49 %/ID vs. 0.97 %/ID), spleen (0.21 %/ID 
vs. 0.9 %/ID) and the primary tumour (1.4 %/ID vs. 3.4 %/ID). 
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5.3.2 Kinetics of S100A8/A9 release during malignant disease 
We examined mice at different time points after tumour inoculation using S100A9-
SPECT scanning. Imaging was performed at an early stage of tumour establishment 
(day 10 after inoculation) and again once the tumour was well-established, and first 
distant metastasis were likely to be present (day 20). 
The tracer accumulation in different body compartments was compared for the 
different time points.  
In the primary tumour, the tracer accumulation, indicative of immune cell activation, 
increased significantly over time. In distant tissues, however, the effects of time and 
continued tumour growth were less pronounced. In lung tissue, local S100A9 
concentration, as depicted by targeted imaging, increased slightly albeit not 
significantly.  
The spleen, only detectable in a few animals at day 10 after tumour induction, was 
clearly detectable in all animals at day 20. 
Unspecific 111In-rabIgG did not reveal perfusion or vessel integrity differences 
between the different time points for any of the examined tissues. 
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Figure 30: Development of local S100A8/A9 concentration over time. 
4T1 tumour-bearing mice were examined by S100A9-SPECT on day 10 (light grey) and day 20 (dark 
grey) after tumour inoculation (n=15). The systemic tracer distribution was assessed using SPECT 24 h 
after iv injection of 111In-aS100A9. The accumulation in the tumour was stronger at day 20 as compared 
to day 10 (3.9 %/ID vs. 2.4 %/ID). Differences in lung tissue were less pronounced (2.3 %/ID vs. 1.5 
%/ID); the blood pool, represented by the heart and kidney signal was virtually identical. The strongly 
elevated signal in the liver on day 20 after tumour implantation can be an indicator of immune cell activity 
in the liver, e.g. in the context of developing liver metastasis. It would require analysis of liver tissue for 
changes in the cellular composition and/or accumulation of circulating tumour cells to further differentiate 
this finding. 
 
5.3.3 Association of S100A8/A9 release and metastatic capability 
We established a model of graded malignancy, represented by variation in the 
capacity to form and establish distant metastasis. The model is based on single cell 
clones from a spontaneous murine breast cancer, isolated from Balb/c mice. The two 
cell lines that have been chosen for this project are the cell lines 4T1.2 and 67NR. 
While 4T1.2 tumours form lung and lymph node metastasis within a few weeks of 
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tumour induction in orthotopic location, 67NR exhibits local growth only. The local 
growth characteristics of both cell lines are virtually identical. 
At day 10 after tumour inoculation, mice bearing either 4T1.2 or 67NR tumours were 
examined using 111In-aS100A9-SPECT. The tracer distribution and resulting signal 
were evaluated in vivo and validated ex vivo using gamma counting of harvested 
tissue samples. 
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Figure 31: S100A9 SPECT imaging in 4T1 or 67NR tumour-bearing animals 
Exemplary images show the difference between 4T1 (n=18) or 67NR (n=8) tumour bearing animals 
(tumours implanted in the mammary fat pad) in systemic S100A8/A9 distribution as depicted by SPECT 
imaging, 24 h after iv injection of 111In-aS100A9: While in 4T1 tumour-bearing animals (dark grey) strong 
tracer accumulation can be observed in spleen and lung, 67NR tumour-bearing animals (light grey) do 
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not exhibit a similarly pronounced pattern (lungs: 0.95 %/ID vs. 0.55 %/ID; spleen: 0.93 %/ID vs. 0.6 
%/ID). Tracer accumulation in target organs of metastasis and the spleen as mirror of the systemic 
monocyte differentiation is only slightly higher than in healthy controls. Unspecific accumulation in liver, 
heart (blood pool) and kidneys/bladder does not exhibit significant differences between the two tumour 
entities. 
 
Separate analyses were performed for the primary tumour, spleen and lungs and 
111In-rabIgG-mediated SPECT served for discrimination of unspecific tracer 
distribution. The perfusion levels as depicted by rabIgG-SPECT were not significantly 
different between 4T1 and 67NR tumour-bearing animals. 
 
 
Figure 32: 111In-rabIgG-driven SPECT in animals bearing 4T1 or 67NR tumours. 
No significant differences between 4T1 (dark grey; n=7) and 67NR (light grey; n=7) tumour-bearing 
animals (tumours implanted in the mammary fat pad) could be detected by rabIgG SPECT (iv injection 24 
h prior to imaging), thereby attributing the differences, detected by S100A9 SPECT to differences in local 
S100A8/A9 concnetration. 
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In accordance with results from the fluorescence imaging experiments, the specific 
tracer accumulation in the tumour already was different for the two tumour entities 
with a higher signal in 4T1.2 tumour lesions as compared to less malignant 67NR. 
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Figure 33: In vivo S100A9 SPECT – focus on the lungs. 
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The comparison of aS100A9 accumulation in the lungs of healthy controls (n=5), 67NR (n=8) and 4T1 
(n=18) tumour-bearing animals revealed a significantly higher S100A9 concentration in the lungs of 4T1 
tumour-bearing animals as compared to the two other groups (0.49 vs. 0.55 vs. 0.95 %/ID; *=p< 0.05). 
 
Similarly, the S100A9-signal in lung tissue and spleen was higher for 4T1 tumour-
bearing animals as compared to 67NR tumour-bearing littermates. 
In spleen tissue, the effects of 67NR tumours were less pronounced than the effects 
of 4T1.2 tumours. 
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Figure 34: rabIgG SPECT to control for specificity of aS100A9-mediated in vivo imaging. 
111In-rabIgG did not allow for detection of physiological differences between the lungs of healthy controls 
(n=4) or tumour-bearing animals (67NR – n=7; 4T1 – n=7). 
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The 111In-rabIgG-mediated signal in the lungs of 67NR tumour-bearing animals did not 
exceed the 111In-aS100A9 signal in healthy animals. 
 
5.3.4 Source of S100A8/A9 
Tissue samples from lungs, spleen and primary tumour from both, 67NR and 4T1.2 
tumour-bearing animals have been analysed for S100A8/A9 positive cells and cell 
populations, which were different in number as compared to healthy control animals. 
Cell suspensions from tissue samples were stained for a combination of immune cell 
markers and analysed, using FACS. Presence and spatial association of cells in the in 
vivo situation were consecutively assessed and validated using fluorescence 
microscopy, using a combination of respective markers. 
The increased S100A9 signals in the spleen of 4T1.2 and 67NR tumour-bearing 
animals were accompanied by splenomegaly and changes in the cellular composition 
of the splenic cell populations.  
 
 
Figure 35: Examination of the spleen of healthy and tumour-bearing animals. 
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The tumour-induced splenomegaly is clearly visible on exemplary resected organs of tumour-bearing 
animals as compared to healthy controls. The FACS analysis of single cell suspensions of these organs 
reveals a strongly increased and aberrant cellularity. 
 
 
Figure 36: Phenotypic analyses of spleen tissue. 
Comparing the CD3- CD19- population (non T-cells, non B-cells) in healthy controls (white; n=9), 67NR 
tumour-bearing animals (light grey; n=15) and 4T1 tumour-bearing animals (black; n=25) with regards to 
the abundance of different immune cell markers, a more than two-fold increase in the number of CD11b+ 
(monocytic) cells could be detected (upper panel). Fostering this impression, CD14 is overexpressed in 
this population as well (middle panel). The expression of F4/80 as a marker for mature macrophages 
however, is significantly reduced (bottom panel). 
**=p<0.01; ***=p<0.001 
 
A significant increase in the frequency of CD3-CD19-CD11b+CD14+monocytes could 
be observed in 67NR and 4T1.2 tumour-bearing mice at day ten after tumour 
inoculation. Monocytes in tumour-bearing mice were on average less differentiated as 
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Figure 37:FACS analysis of splenic cells in tumour-bearing mice – T- and B-cells. 
The CD3+ population of T cells was reduced by a factor of around two (40% vs. 19% vs. 17%; *=p<0.05; 
***=p<0.001) in 67NR  (grey; n=15) or 4T1 (black; n=25) tumour-bearing animals as compared to healthy 
controls (white; n=9) while the CD19+ B-cell population did not show a significant variation (40% vs. 32% 
vs. 36%). 
 
Similarly representative of a less differentiated phenotype of myeloid cells, 
splenocytes in tumour-bearing mice showed an increased expression of CD80 and a 
reduced expression of MHC II as compared to healthy controls (40).  
We further characterised the phenotype and function of the monocyte population that 
we found increased in association with elevated S100A8/A9 tracer levels in SPECT. 
We harvested spleens from tumour-bearing animals and analysed the cellular infiltrate 
in comparison to tissue samples from healthy controls. FACS staining for several cell 
surface markers allowed us to define a subset of the increased monocyte (CD3-CD19-
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CD11b+CD14+) population first in the spleens of tumour-bearing animals and 
consecutively also in the premetastatic lung tissue. 
 
 
Figure 38: Characterisation of tumour-induced monocytes in spleen tissue. 
Among all live cells in the spleen, a population of Gr-1+ CD115+ cells (upper right quadant in FACS 
plots) was significantly increased in tumour-bearing, as compared to healthy animals (upper panel; 0.3 
vs. 1.2 vs. 1.8 %). In this population, cells with the phenotype CCR2+ CX3CR1low were significantly 
more abundant in tumour-bearing animals than in healthy controls and moreover more abundant in 
animals, bearing highly malignant 4T1 tumours (0.025 vs. 0.5 vs. 0.75 %). 
*=p<0.05; ***=p>0.001 
 
Presence of this specific cell population was different in 67NR as compared to more 
metastatic 4T1.2 tumour-bearing animals and provided an immunological correlate for 
the differences in in vivo imaging between the two models. This particular monocyte 
population, increased in tumour-bearing animals as compared to healthy controls was 
positive for Gr-1 and CD115 – defining a monocyte before full differentiation. The cells 
moreover expressed a phenotype including high expression of CCR2 and low 
positivity for CX3CR1, defining pro-inflammatory monocytes (121). Further markers, 
found in this population included CD62L, CD49d, CD11b and interleukin-4 (IL-4) 
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receptor. In summary, the marker combination suggested them to be part of or at 
least associated with the heterogeneous family of MDSCs (122).  
This Gr-1+CD115+CCR2highCX3CR1lowmonocyte population was also positive for 
S100A8/A9 by intracellular FACS staining. Complementary confocal microscopy 
analysis of frozen spleen sections showed intracellular and extracellular S100A8/A9 in 
areas surrounding CD115+CCR2+ cells. 
 
 
Figure 39: Tumour-induced monocytes are S100A8/A9 positive and release S100A8/A9. 
Within the aforementioned Gr-1+CD115+CCR2highCX3CR1low monocyte population, a strong positivity for 
intracellular S100A8/A9 could be detected (exemplary plot in A; quantification in B for control/67NR/4T1 
n=9/15/25). The amount of intracellular S100A8/A9, as reflected by the mean fluorescence intensity, was 
not significantly different for monocytes from healthy controls or tumour-bearing animals. A slightly lower 
signal in those cells, isolated from 4T1.2 tumour-bearing animals could reflect a higher S100A8/A9 
release in those animals. Confocal microscopy revealed extracellular S100A8/A9 (yellow) in the vicinity of 
CD11b+CCR2+ cell clusters. 
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5.3.5 Association of S100A9 imaging and MDSC abundance 
The frequency of Gr1+CD115+CCR2highCX3CR1low monocytes in lungs, spleen and 
tumour tissue correlated with the respective metastatic potential of the underlying 
model: monocyte levels in tumour tissue as well as the periphery were significantly 




Figure 40: Gr1+CD115+CCR2highCX3CR1low monocytes in tumour tissue and peripheral blood. 
FACS analyses of samples from primary tumour tissue as well as peripheral blood reveal 
Gr1+CD115+CCR2highCX3CR1low monocytes in higher numbers in 4T1.2 tumours (n=18) as compared to 
67NR tumours (n=8; =p<0.05), confirming the in vivo imaging results and in the blood of tumour-bearing 
as compared to healthy control animals (n=9). Although the exemplary FACS plots suggest a strong 
difference between the two tumour entities, no significant difference between the MDSC abundance in 
peripheral blood could be detected between 67NR and 4T1.2 in the final, comprehensive analysis 
(***=p<0.001). 
 
 In vivo S100A9-SPECT imaging showed a significantly higher tracer uptake in the 
lungs of 4T1.2-tumour bearing mice as compared to 67NR-tumour-bearing mice and 
controls (fig. 34), reflecting the increased MDSC abundance.  
 
	   111 
 
Figure 41: Abundance of Gr1+CD115+CCR2highCX3CR1low monocytes in premetastatic lung 
tissue 
Resembling the analysis of spleen tissue, MDSC can be found in significantly higher amounts in 
premetastatic lung tissue of tumour bearing animals (67NR: 2.2% of live cells; 4T1.2: 3.5%; n=8/18; 
p<0.05) as compared to the lungs of healthy controls (1.1%; n=9; p<0.001). Metastatic 4T1.2 tumours 
induce a higher infiltration of lungs by MDSC than non-metastatic 67NR. 
  
Confocal microscopy of frozen lung sections revealed intra- and extracellular S100A9 
in areas of CCR2+CD115+ monocyte accumulation. As compared to tissue samples of 
healthy controls or 67NR tumour-bearing mice, samples of 4T1.2 tumour-bearing 
animals exhibited an increased staining for extracellular S100A9, confirming the in 
vivo imaging findings.  
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Figure 42: Confocal microscopy of premetastatic lung tissue. 
In the lungs of tumour-bearing mice, clusters of CD115+CCR2+ cells could be detected in colocalisation 
with released S100A8/A9. The abundance of such clusters was higher in highly malignant tumour-
bearing animals than in controls, confirming the in vivo SPECT imaging results. 
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5.3.6 Changes under CCL2 blocking 
The CCR2-CCL2 signalling axis has previously been implicated in metastatic breast 
cancer cell seeding in the lungs (123). In response to CCR2-mediated signalling, 
tumour-associated monocytes accumulate in the primary tumour microenvironment as 
well as at metastatic sites (124). The blockade of CCR2-binding seems to inhibit the 
initialisation of a premetastic niche (125). With established effects on metastatic 
tumour cell seeding and established blocking procedures to adapt for this study, the 
CCL2-CCR2 signalling axis was an ideal target to assess S100A9-imaging for 
visualisation of the effects of therapy and intervention. 
 
Upon in vitro stimulation with recombinant CCL2, monocytes (Gr-
1+CD115+CCR2highCX3CR1low), derived from spleens of 4T1 tumour-bearing mice, 
secreted a significantly higher amount of S100A8/A9 in comparison to cells, derived 
from 67NR tumour-bearing mice. Matched samples of granulocytes (Gr-
1+CR2+CD115-) did not increase secretion of S100A8/A9 in response to CCL2 
stimulation. 
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Figure 43: S100A8/A9 release upon CCL2/CCR2 stimulation. 
Cells, isolated from either 67NR or 4T1.2 tumour-bearing animals were stimulated with CCL2 (black bars) 
or examined without further treatment (white bars). The resulting release of S100A8/A9 was determined 
by ELISA. CCL2-stimulation resulted in strong S100A8/A9 release from Gr-1+CD115+CCR2+CX3CR1low 
monocytic cells, while no significant increase in the release of S100A8/A9 could be observed from 
granulocytic (CD115-) cells or MDSC from 67NR animals (*=p<0.05)  
 
It has been shown earlier, that CCL2 acts as a chemo-attractant for MDSC (126). In 
this context, blockade of the CCL2-CCR2 signalling axis should decrease the 
recruitment of Gr-1+CD115+CCR2highCX3CR1lowmonocytes to premetastatic lung 
tissue as well as the SPECT-detectable S100A8/A9 in vivo imaging signal.  
CCL2-blocking with blocking antibodies according to established treatment protocols 
indeed induced a significant reduction of the specific tracer accumulation in spleens 
and lungs of 4T1.2 tumour-bearing animals as depicted by in vivo SPECT imaging.  
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Figure 44: In vivo S100A9 SPECT imaging under CCL2/CCR2 blockade – lung tissue 
In the lung tissue of 4T1 tumour-bearing animals, the treatment with aCCL2 (bottom panel; black bar on 
graph; n=9) significantly reduced S100A8/A9 release, as depicted by specific SPECT, as compared to 
controls, treated with unspecific IgG (upper panel; white bar on graph; n=6; 2.1 vs. 1.45 %/ID; p< 0.001).  
 
 
Figure 45: In vivo S100A9 SPECT imaging under CCL2/CCR2 blockade – spleen tissue. 
Confirming the in vivo imaging results, presented before, a reduction of S100A8/A9 release under 
CCL2/CCR2 blockade was also detectable in the spleens of tumour-bearing animals (n=9/6; 0.95 vs. 
0.55 %/ID; p<0.05).  
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The concomitant FACS analyses of tissue samples confirmed the in vivo imaging 
results and revealed a significant reduction of Gr1+CD115+CCR2highCX3CR1low 
monocytes as compared to those animals, which received an ineffective control 
treatment only.  
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5.3.7 The cellular microenvironment, effects on Treg and NK cells 
The increased frequency of Gr-1+CD115+CCR2highCX3CR1lowmonocytes in the lung 
tissue of tumour-bearing mice was associated with an increased presence of 
CD25+Foxp3+Treg cells. Compared to healthy controls, the increase was more 
pronounced in 4T1.2 tumour-bearing mice, while an only limited effect on the 
pulmonary Treg population could be observed in 67NR tumour-bearing animals.  
 
 
Figure 46: Treg in lung tissue of healthy and tumour-bearing mice. 
Exemplary FACS plots for CD25+Foxp3+ cells in lung tissue from healthy control animals (n=9), 67NR ( 
n=8) and 4T1.2 (n=18) tumour-bearing animals reveal a significant, almost two-fold increase in Treg in 
the lungs of those animals, bearing highly malignant tumours, as compared to controls and low-
malignancy tumours (*=p<0.05). 
 
Tregs play a pivotal role in controlling inflammation by inhibiting the proliferation and 
cytotoxic activity of NK cells (127, 128). To assess the activity of NK cells under the 
influence of MDSC and Treg in the premetastatic microenvironment, the frequency 
and degranulation of NK cells, isolated from lung tissue of tumour-bearing and healthy 
control mice, was assessed. Inversely mirroring the increase in immunosuppressive 
Treg activity in the pre-metastatic lung tissue was a concomitant decrease in the 
number of NK cells. Although the differentiation state of NK cells was not affected, 
their activation state, as indicated by staining for CD107 (LAMP1) as a measure for 
degranulation function (129), was significantly impaired in the presence of Treg and 
Gr-1+CD115+CCR2highCX3CR1lowmonocytes.  
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Figure 47: NK cell abundance and function in premetastatic lung tissue 
The number of NK cells in the lung tissue of 67NR (n=8) or 4T1 (n=18) tumour-bearing mice was 
significantly reduced as compared to healthy controls (n=9; upper panel; *=p<0.05; ***=p<0.001). Those 
cells, present, exhibited a limited function (bottom panel), as reflected by the expression of NK cell 
activity marker LAMP1.  
 
These results are supported by earlier work from Huang et al and others, showing a 
direct correlation between the accumulation of monocytes/MDSC in tumour tissue and 
the consecutive development of a Treg-mediated immunomodulatory environment 
that impairs potential anti-tumour immune activity (130).  
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5.3.8 Correlation of S100A9 in vivo imaging and metastatic burden 
To assess the predictive and prognostic potential of S100A8/A9 imaging, a 
representative group of mice, bearing 4T1.2 tumours, was followed after initial in vivo 
imaging at day 10 and re-examined at day 20 after tumour inoculation. 
Tissue samples from the lungs were screened for mCherry-positive tumour cells, 
confirming metastatic spread. FACS sorting of cell suspensions from the tissue 
samples enabled for quantification of the metastatic deposit. 
At the time of in vivo imaging, 10 days after tumour inoculation, screening of tissue 
samples from 4T1.2 tumour-bearing animals for mCherry-positive tumour cells 
confirmed the premetastatic state of malignant disease: no tumour cells, 
representative of a local metastatic deposit, could be detected in any of the samples:  
the mCherry+ fraction in lung tissue was <0.1% for both, healthy controls and tumour-
bearing animals. At the second investigated time point (day 20), mCherry-positive 




Figure 48: FACS screen for tumour cells in lung tissue. 
In the lungs of 4T1 tumour-bearing mice, the FACS screen for mCherry+ tumour cells was negative at 
day 10 after tumour inoculation (0.08% of live cells; healthy control: 0.05%; n=4), confirming that this time 
	   120 
point represents a premetastatic phase of malignant disease. In contrast, a measurable colonisation of 
the lungs by tumour cells was evident at day 20 after tumour induction (0.42% of live cells; n=11; 
p<0.001).  
 
Comparison of the in vivo imaging data from day 10 with the quantitative data on the 
individual metastatic burden revealed, that increased S100A9-levels, as depicted by 
SPECT imaging at day 10 after tumour implantation, were indicative of the tumour-
mediated immune remodelling and correlated significantly with the consecutive 
tumour cell seeding into the lung (r2 = 0.79; p<0.0001). 
 
 
Figure 49: Correlation of S100A9 SPECT and metastatic development. 
The aS100A9-driven SPECT , obtained in the premetastatic phase of disease at day 10 after tumour 
induction, correlated with the consecutive metastatic burden as represented by the number  of mCherry+ 
cells in the lung tissue (n=11; r2= 0.79; p<0.0001). To increase variation and assess the sensitivity of 
aS100A9 imaging, seven aCCL2-treated animals (red dots) have been included in the analysis.  
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Local release and concentration of S100A8/A9, as a marker of premetastatic tissue 
priming, is indicative of immune cell activity in premetastatic lung tissue that favours 
and drives colonisation of lung tissue by circulating tumour cells.  
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5.4 Discussion  
5.4.1 Review of Results 
A syngeneic, orthotopic model system for metastatic breast cancer has been 
established, using tumour cell lines with a common genetic background. The two cell 
lines 4T1.2 and 67NR represent high and low grade breast cancer respectively (83). 
The comparison of data from the two models allows for an estimation of the results 
that are to be expected in heterogeneous spontaneous disease. Engineering of the 
cell lines for expression of mCherry allowed for retrospective confirmation of the 
absence of metastasis/tumour cell deposits in distant tissue at day 10, and estimation 
of the metastatic burden at day 20 after tumour inoculation (Fig. 49). 
Both, 4T1.2 and 67NR tumours, exhibited effects on the immune system of tumour-
bearing animals. Splenomegaly and a change in spleen cellularity occurred in both 
tumour entities, although the effects were significantly more pronounced in 4T1.2 
tumour-bearing animals (Fig. 36).  
A specific population of monocytes, with the phenotype 
Gr1+CD115+CCR2highCX3CR1low was distinctly increased in tumour-bearing 
animals in spleen and lungs at day 10 after tumour inoculation already (Figs. 39, 42). 
The monocyte was positive for S100A8/A9 and released the heterodimer upon 
stimulation with CCL2. Release was higher in cells, isolated from 4T1.2 tumour-
bearing animals than from 67NR tumour-bearing animals or controls (Figs. 40, 44). 
The presence of this particular cell type was associated with an increased presence of 
Treg (Fig. 47) and a reduced activity of NK cells (Fig. 48), defining an 
immunosuppressive, tumour-permissive microenvironment. 
S100A9-specific SPECT imaging in tumour-bearing animals allowed for visualisation 
and measurement of S100A9-release in lungs (Fig. 34), spleen and primary tumour. 
The signal was significantly higher in 4T1.2 tumour-bearing animals than in 67NR 
tumour-bearing animals or healthy controls (Fig. 32). The S100A9 signal reflected the 
local MDSC accumulation and correlated with the local abundance of Treg as well as 
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the activity impairment in NK cells, therefore providing a non-invasive readout of 
tumour-mediated immune remodelling in distant, premetastatic tissue. 
CCL2 blockade inhibited MDSC and consecutive Treg accumulation and hampered 
establishment of the described immunosuppressive environment. In vivo S100A9 
SPECT clearly reflected the effects of CCL2 blockade (Figs. 45, 46). 
S100A9 imaging at day 10 after tumour inoculation individually correlated with the 
metastatic burden in lung tissue at day 20 (Fig. 50). 
 
5.4.2 Project results in the context of the premetastatic niche concept 
As pointed out in the introduction already, the idea of tissue priming by the primary 
tumour, preceding metastasis, is not actually new. New are the insights into the 
paramount role of tumour-driven immune remodelling to provide growing tumours and 
metastasis with support and protection in various ways. However, the current models 
of premetastatic niche establishment are largely based on histological analysis of 
tissue samples and therefore lack information on temporal development or correlation 
of initial stages of the metastatic process with the actual outcome.  
Means for non-invasive in vivo visualisation of tumour-mediated immune activity were 
missing so far and therefore, information about the kinetics of premetastatic niche 
establishment have not been available. 
  
S100A8/A9 as an important marker for immunomodulatory myeloid cells like MDSC 
has been established as an indicator of premetastatic niche establishment before. In a 
series of experimental studies, Hiratsuka et al discovered the association of 
S100A8/A9 with premetastatic tissue priming (42, 131). They could demonstrate that 
S100A8/A9, CCL2 and serum amyloid A 3 (SAA3) were upregulated and increasingly 
expressed in lung tissue of extra-pulmonary tumour-bearing mice as well as in cancer 
patient lung tissue samples. Examinations in CCL2 knock out animals led them to the 
conclusion that S100A8/A9 release was in part mediated by the CCL2-CCR2 axis. 
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They have moreover shown S100A8/A9 to stimulate SAA3-mediated MDSC 
recruitment and induction of vascular hyperpemability. The observations, Hiratsuka et 
al describe, match the finding that CCL2 blockade consecutively reduces tumour-
induced S100A8/A9 release in target tissue of metastasis. In return and exceeding the 
results, presented by Hiratsuka et al, a direct and dynamic effect of CCL2 blockade on 
initiation of premetastatic niche foci and more importantly the consecutive tumour cell 
seeding and survival could be demonstrated. 
S100A8/A9 exerts immunomodulatory effects also via toll-like receptor 4 (TLR-4), 
which stimulates MDSC accumulation. In the hypoxic primary tumour environment, 
MDSC express HIF-1α, promoting the generation of tumour-associated macrophages 
and driving neoangiogenesis (132). In the premetastatic niche, S100A8/A9-driven 
recruitment of MDSC exerts effects on cytotoxic T cells and NK cells, dampening the 
anti-tumour immune response that could hamper tumour cell seeding (41). Moreover, 
MDSC express a variety of growth factors that stimulate tumour cell establishment 
(105). Within this study, a possible way to visualise these processes to foster the 
understanding of premetastatic tissue priming has been demonstrated. Additionally, a 
specific population of monocytes within the heterogeneous group of MDSC has been 
characterised in detail. The cells could be confirmed as a source of S100A8/A9 in 
tumour-primed tissue. The local presence of this cell type could be correlated with the 
establishment of the premetastaic niche in the form of impaired immune function and 
expression of bookmarking proteins.  
An association between premetastatic niche establishment – as reflected by 
S100A8/A9 imaging – and the colonisation of primed tissue by circulating tumour cells 
could be demonstrated. 
The established in vivo imaging allowed for determination of local S100A8/A9 release 
in vivo without disturbing the premetastatic system and thus enabled assessment of 
the prognostic potential of S100A8/A9 for the development of metastasis. 
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5.4.3 Potential impact for imaging research, alternative 
targets/methodology 
 
The crosstalk between tumour and immune cells has been recognised to be of major 
importance for tumour spread and development. Current assessment of tumour-
mediated immune cell regulation is based on the quantification of different cell 
subsets in biopsies or surgical excisions (133). Diagnostic markers that allow for non-
invasive, continuous monitoring of tumour-mediated inflammation and tumour-immune 
cell crosstalk are elusive. This precludes optimisation of and selection for cancer 
immunotherapy (4) and moreover hampers further understanding of the temporal 
correlation between different immune-mediated cellular events, preceding the 
establishment of metastasis. 
This study provides the first evidence that S100A8/A9 can be used as a non-invasive 
imaging marker for the establishment of a tumour-permissive, immunosuppressive 
environment in target organs of metastasis. S100A8/A9 release was evident and 
detectable at an early stage of the metastatic process, before tumour cells seeded in 
the lungs of 4T1.2 tumour-bearing mice. Examining this premetastatic niche 
environment, we found an increased number of Treg along with an increase of 
MDSC-like cells in correlation with the in vivo imaging data. Our results are supported 
by studies, showing that MDSCs mediate the development of tumour-induced Foxp3+ 
Treg (130), which are required for the establishment of metastasis (134). One well-
characterised function of MDSCs is their ability to induce anergy and suppress the 
proliferation of effector T cells, either directly or indirectly through the induction of 
Tregs. The combined action of these two cell types could explain our observation of a 
decrease in number and activity of NK cells (135). 
We found a Gr1+CD115+CCR2highCX3CR1low monocyte population as a local source 
of S100A8/A9 under regulation of the CCL2-CCR2 pathway.  
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It has been shown that CCL2 is highly expressed in various murine breast cancer 
models including 4T1 and 67NR (136) as well as the tumour-associated stroma. Lim 
et al summarise in their recent review (137) the extensive research on the role of 
CCL2-CCR2 signalling in breast cancer development and spread. CCL2 directly 
stimulates tumour cell mobility and acts as a potent chemoattractant for MDSC (138) 
and TAM (139).  Under the influence of CCL2, CCR2+ monocytes were driven to aid 
tumour cell extravasation (123). The blockade of CCL2-CCR2 signalling exerted 
effects on both, the primary tumour and metastasis, reducing tumour growth (140) 
and the abundance of distant metastasis (136). In contrast to the experimental 
research results and consecutive expectations, reproduction of the effect of CCL2-
CCR2 blockade in initial clinical trials failed (137). For my study however, the results 
presented are in perfect agreement with prior work on the role of CCL2-CCR2 
signalling in murine breast cancer with the dual effect of CCL2-CCR2 blockade on the 
tumour cell as well as associated immune cells as a potential explanation for the 
drastic effect on metastatic spread.  
Our data suggest a correlation between malignant potential of the tumour (the more 
metastatic 4T1.2 vs the non-metastatic variant 67NR), abundance of the 
aforementioned Gr1+CD115+CCR2highCX3CR1low monocyte population in pre-
metastatic lungs and spleen, as well as the levels of released, SPECT-detectable 
S100A8/A9 in these organs.   
The relevance of S100A8/A9 in malignant disease has also been highlighted by 
studies of Cheng et al, who have shown that S100-deficient animals present a 
reduced generation of Gr-1+CD11b+ MDSCs, resulting in a decreased growth of 
lymphomas and sarcomas (37). The important role for S100A8/A9 in priming organs 
such as the brain and lung for metastatic predisposition has been demonstrated in 
murine breast cancer models (41, 141). In addition, clinical studies of patients with 
high grade and invasive breast tumours have shown that S100A8/A9 can serve as 
marker of poor prognosis (100, 142). Despite the lack of a signal peptide sequence, 
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S100A8/A9 is actively delivered to the tumour microenvironment and distant tissues 
via exosomes that are secreted by tumour-associated immune cells such as MDSC 
(43).  Upon release, S100A8/A9 promotes the accumulation of MDSC (40), thereby 
orchestrating an immunosuppressive microenvironment in premetastatic tissue, 
optimal for tumour cell deposition and growth (41, 42). In agreement with these 
previous studies, we demonstrated by in vivo SPECT imaging, supplemented by 
FACS analyses and histology, increased S100A8/A9 levels in pre-metastatic lung 
tissue, and a concomitant accumulation of MDSC-like pro-inflammatory monocytes, 
followed by an infiltration of the lung by circulating tumour cells. Taken together, the 
S100A9 specific imaging proved indicative of tumour-mediated immune cell activity in 
premetastatic tissue and correlated with the subsequent metastatic tumour burden at 
an individual animal level. Further studies will be necessary to assess which factors 
influence the S100A8/A9 expression in premetastatic tissue, and moreover assess 
additional effects on the local immune infiltrate and tumour cell seeding and growth in 
the premetastatic niche. So far, S100A8/A9 imaging can only serve as an indicator of 
tumour-induced inflammation, coincident with systemic tumour spread. It will be future 
work to establish the immediate link and test S100A8/A9 as a predictive marker for 
systemic tumour spread. 
Previously, markers Gr-1, CD11b and CD115 have been used to identify tumour-
induced MDSCs (123, 143). We have further specified this phenotype. The use of 
additional markers CCR2 and CX3CR1 allowed us to define a specific MDSC-like 
monocyte population, induced in our tumour model and to give a hint towards possible 
regulation. The cell type we found increased in accordance with the malignant 
potential of induced tumours shares surface markers of active, pro-inflammatory 
monocytes, but lacks markers for mature macrophages. In fact, we find the ratio of 
immature to mature cells of monocytic origin shifted towards immature phenotypes – 
in line with reports that tumours promote an arrest of certain cell types in immature 
stages (144), including MDSC.  
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In addition to S100 proteins (including family members 1, 2 4, 7, 8, 9, and 11), 
chemokines and chemokine receptors are among the soluble factors that contribute to 
lung metastasis in cancer. Hiratsuka et al., have recently shown that primary tumours 
are able to induce changes in vascular permeability, preparing homing sites for 
circulating, metastatic tumour cells (131). The CCL2-CCR2 axis seems to be crucial in 
this process. CCL2, secreted by tumour-associated fibroblasts induces the attraction 
of monocytes and monocyte-like cells, the mobilisation of bone marrow-derived 
myeloid cells (123, 131) and tumour-associated fibroblasts (126, 145). We show that 
Gr-1+CD115+CCR2highCX3CR1low monocytes secrete S100A8/A9 upon stimulation 
with recombinant CCL2, highlighting another potential pro-metastatic function of 
CCL2. There are probably other producer cells for S100A8/A9 in the tumour 
microenvironment but we have previously excluded tumour cells as the source, by 
analysis of cell lysates and tissue culture supernatants, and by FACS which showed 
virtually all S100A9+ cells found in the 4T1.2 model, to be CD11b+(80). Metastatic 
breast cancer is known to secrete CCL2 (146), which can stimulate MDSC-like pro-
inflammatory monocytes and trigger S100A8/A9 release. This would establish a 
positive cooperativity between S100A8/A9 and the CCL2-CCR2 pathway. Exosomal 
S100A8/A9, released upon CCL2 stimulation in the primary tumour, can be delivered 
systemically to the pre-metastatic lung endothelium, and potentially stimulate the 
paracrine production of mediators such as serum amyloid A 3 (SAA3), attracting 
further CD11b+ myeloid cells to the lung niche (42). The effects of in vivo blocking of 
CCL2 activity highlighted the importance of this positive cooperativity in our model. 
Treatment with CCL2 blocking antibodies resulted in reduced S100A8/A9 expression 
and a significantly decreased number of pro-inflammatory monocytes in both spleen 
and lungs of 4T1.2-tumour bearing mice. Clinically, blocking antibodies to CCL2 such 
as Carlumab (Johnson & Johnson, New Brunswick, NJ, USA), are now being tested in 
clinical trials; treatment was well tolerated and preliminary anti-tumour activity of this 
approach in advanced cancer patients could be observed (147, 148). 
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The way of delivery of S100A8/A9 to the premetastatic niche is still to be determined. 
Analyses of the content of exosomes from tumour patients show S100A8/A9 as one 
of the major components, present in much higher concentrations than in exosomes 
from healthy controls (43, 149). Integrating these findings, it is reasonable to believe 
that, together with other biologically active proteins and DNA/RNA fragments, 
S100A8/A9 is systemically distributed from the primary tumour environment to 
potential sites of metastasis encased in exosomes. It will be future work to evaluate 
this hypothesis and assess the role of exosomes in mediating tumour-associated 
inflammation and tumour-induced immune cell activity in premetastatic tissue.   
The use of S100A8/A9 as a clinical marker for cancer immune modulation and 
translation of a specific imaging approach will depend in part on further development 
of the tracer. Since the S100A8/A9 molecular target is extracellular, full-length 
antibodies are expected to have good access to it. Nevertheless, full-length antibodies 
are only slowly eliminated from the blood pool, leading to a long period between tracer 
application and imaging with reasonable contrast to unspecific background signal 
requiring isotopes with a long half-life. Smaller targeting compounds – either antibody 
fragments or non-peptidic small molecules should in this context be evaluated. A 
small molecule, binding S100A8/A9, would potentially exhibit a more rapid clearance 
from the blood pool and faster accumulation in the target tissue, hence enabling for 
the use of short-lived isotopes for clinical PET imaging. As an example, the small 
molecule Tasquinimod (MW 406 g/Mol), binding S100A8/A9 and inducing a 
conformational change of the heterodimer, is almost completely eliminated from 
plasma as well as liver and kidneys within 24 hours after application (150). Labelling 
of such compounds for other imaging modalities for clinical or preclinical use would 
also be conceivable. Moreover, a correlation with conventional tumour grading and 
serum markers for tumour development would foster the clinical use of S100A8/A9 as 
a marker for patient stratification and a prognostic potential as indicated by our 
results. 
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For cancer therapy, experimental cancer research and drug development, an 
opportunity to follow immune cell activity in a specific way over time will have a 
significant impact. For instance, despite the success and exciting potential of new 
therapeutic agents, such as monoclonal anti-PD1 or anti-CTLA-4 blocking-antibodies 
(4), response varies greatly (92) and non-invasive tools for monitoring of the 
conditioning of micrometastatic niches are needed to further optimise therapy and to 
sustain survival benefits in patients. As a paradigm for such future work, we suggest 
S100A8/A9 in vivo imaging as a first approach to non-invasively address tumour 
immune crosstalk. Clinical establishment of this technique could fundamentally 




S100A8/A9 has been described as a marker for immune cell activity in inflammation 
and cancer and a crucial player in tumour-mediated immune remodelling. Using 
S100A8/A9 release in vivo as readout for tumour-driven recruitment of immune cells, 
the activity of directly tumour-associated immune cells as well as the processes in 
premetastatic tissue can be observed. As S100A8/A9 is a mediator of MDSC-driven 
immunosuppression, it can also serve as an indicator for the consecutive immune 
modulation, effecting T- and NK cells. By establishing S100A9 imaging in the primary 
tumour microenvironment using OI and systemically, using SPECT, a first method for 
continuous monitoring of tumour-mediated immune cell activity is suggested. 
 
The objectives of this study, as formulated in the introductory chapter, were 
1. To establish S100A8/A9 as a marker for local tumour immune interaction 
It could be shown that the local concentration of S100A8/A9 closely reflects 
the local abundance of immunomodulatory monocyte derivatives including 
MDSC in e.g. the primary tumour microenvironment. The potential of a tumour 
	   131 
lesion to attract and activate immunomodulatory monocytes (67NR vs. 4T1: 
1.2% vs. 8.7% activated monocytes) was coincident with the cell line specific 
malignant potential and was reflected by S100A9-specific OI (67NR vs. 4T1: 
250.8 vs. 427.3 AU; p<0.05). The individual S100A9 imaging signal as an 
indicator of local immune cell activity correlated with the individual tumour 
development (r2=0.86; p<0.0001). 
 
2. To develop a S100A9-specific radiotracer 
A radiotracer for labelling with 111In has been produced from the established 
fluorescent optical tracer version, described earlier (79, 82). The tracer has 
been tested for stability under physiological conditions in vitro and in vivo 
performance in a murine model of inflammation before application in models of 
malignant disease (inflammatory focus: 111In-aS100A9 vs. 111In-rabIgG: 3.9 vs. 
1.1 %/ID; p<0.001; healthy control: 0.76 vs. 0.89 %/ID; not significant). 
 
3. To establish systemic S100A9-specific in vivo imaging in cancer 
111In-aS100A9 has been successfully used for visualisation of systemic 
S100A8/A9 release in tumour-bearing animals. The tracer distribution was 
reflective of disease-related alteration of immune cell variety and activity in 
tumour, lungs and spleen of tumour-bearing animals (see chapter 5 for details 
on the malignant microenvironment). S100A9-specific SPECT imaging proved 
indicative of the establishment of an immunosuppressive microenvironment in 
premetastatic lung tissue (healthy lung vs. 67NR vs. 4T1.2: 0.49 vs. 0.55 vs. 
0.95 %/ID; p< 0.05), constituted by an increased accumulation of MDSC (1.1% 
vs. 2.2% vs. 3.5% of live cells) and Treg (0.6% vs. 0.6% vs. 1.4%) and a 
reduction in number and activity of anti-tumour NK cells (6.8% vs. 4.7% vs. 
2.4%; activity: 300 vs. 190 vs. 120 MFI for CD107 staining).  
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4. Understanding pre-metastatic niche establishment 
The precise system of regulatory mechanisms behind premetastatic tissue 
priming and the major regulators of premetastatic niche establishment are still 
widely unknown. Within this study however, we could ascertain that the 
CCL2/CCR2 signalling axis is one of potentially several regulatory pathways 
that can be addressed for interference with tumour-associated immune activity 
and tissue priming and that S100A9 imaging allows for visualisation of the 
effects of this intervention (CCL2 blockade vs. untreated control: 1.45 vs. 2.1 
%/ID; p< 0.05). With S100A9-imaging being indicative of metastatic 
development on the basis of premetastatic niche establishment (correlation 
S100A9 signal vs. metastatic burden: r2=0.79 p<0.0001), this method holds 
the potential for future evaluation of regulators of tumour spread. 
 
The imaging methodology, established within this project, will enable studying of 
further mediators and regulators of tumour-immune interaction and tumour-mediated 
tissue priming. S100A8/A9 is a potent marker for monocyte activity and in this context 
the activity and abundance of major effectors of tumour-associated inflammation (e.g. 
MDSC) and can serve as readout for intervention and knock-out studies. 
So far, we have assessed 100A9-specific imaging for visualisation of tumour-
associated inflammation in primary tumour lesions and tumour-induced immune cell 
activity in distant tissue. The individual, local S100A9 imaging signal allowed for 
estimation of tumour growth and metastatic development in a selected, syngeneic 
model of metastatic breast cancer in mice. Although this model – due to the 
syngeneic character and performance in wild type animals – is considered better 
suited to represent the situation in humans than for example tumour models that 
require immunocompromised animals, further studies will be required to foster 
S100A9 imaging as a potentially translatable biomarker for the human system. One 
aspect that needs further clarification in this context is the role of specific immune cell 
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populations and whether or not these roles are comparable between mice and 
humans: While in mice the granulocytic MDSC dominates the tumour 
microenvironment, the monocytic MDSC is more abundant in humans. Whether this 
fact has an influence on the induction and maintenance of an immunosuppressive, 
tumour-permissive environment needs to be addressed. 
 
We could show that the S100A9 imaging signal reflects changes of the 
immunosuppressive microenvironment, constituted by blockade of the CCL2/CCR2 
signalling cascade. Future work will haver to cover other important signalling routes 
that have already been explored for therapy but not diagnostic purposes. It needs to 
be answered whether S100A8/A9 in tumour tissue and/or the target tissue of 
metastasis is suited as a marker for immunomodulatory therapy on a broad basis. 
Moreover, different stages of therapy response need to be assessed separately to 
control for adverse effects on the S100A8/A9 expression by, for example, 
inflammatory cells, reacting to increased cell death in the successfully treated tumour. 
On the cellular level, consecutive studies will examine whether blockade of signalling 
cascades that promote the establishment of the premetastatic niche also inhibit 
tumour cell shedding from the primary tumour and whether or not the phenotype of 
monocytic and T cells recovers under therapy. 
S100A9 imaging can play a pivotal role in research on metastatic tumour growth and 
provide an important tool for future studies: In searching for the mediators and 
communication pathways between the tumour and the target tissue of metastasis, 
S100A9 imaging can provide a read out for biological effects on tumour-associated 
immune cells. In consecutive studies, potential means of tumour-tissue 
communication can be assessed for their effect on S100A8/A9 release as depicted by 
target-specific imaging. 
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The importance of premetastatic tissue priming and the potential of S100A8/A9-
imaging as a diagnostic tool are underlined by the observation that processes, 
preceding metastasis (immune cell infiltration and activation in lung tissue) predict the 
consecutive extent of disease. In patients, a comparable tool would enable for 
identification of patients, prone for metastatic development and therefore in need of 
closer monitoring and specific therapy.  
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AU Arbitrary units 
BSA Bovine serum albumin 
BSU Biological services unit 
CD Cluster of differentiation 
CSF Colony stimulating factor 
CT Computed tomography 
DAMP Damage associated molecular pattern 
DC Dendritic cell 
DMEM Dulbecco’s modified Eagle medium 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
ELISA Enzyme linked immunosorbant assay 
FACS Fluorescence activated cell sorting 
FBS Fetal bovine calf serum 
FMO Fluorescence minus one 
FMT Fluorescence mediated tomography 
FRI Fluorescence reflectance imaging 




HIF Hypoxia-inducible factor 
HPLC High performance liquid chromatography 
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IBD Inflammatory bowel disease 
ICD Irritant contact dermatitis 
ID Injected dose 
IgG Immunoglobin G 
IL Interleukin 
IMC Immature myeloid cell 
M-CSF Macrophage-colony stimulating factor 
MACS Magnetic activated cell sorter 
MDSC Myeloid derived suppressor cell 
MHC Major histocompatibility complex 
MIP Macrophage inflammatory protein 
miRNA Micro ribonucleic acid 
MMP Matrix metallopreoteinase 
MRI Magnetic resonance tomography 
mRNA Messenger ribonucleic acid 
MRP Myeloid related protein 
MW Molecular weight 
NIR Near-infrared 
NIRF Near-infrared fluorescence 
NK cells Natural killer cells 
NO Nitric oxide 
OCT Optimum cutting temperature compound 
OI Optical imaging 
PBS Phosphate buffered saline 
PET Positron emission tomography 
PN Premetastatic niche 
RA Rheumatoid arthritis 
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rab Rabbit 
ROI Region of interest 
ROS Reactive oxygen species 
SAA Serum amyloid A 
SLE Systemic lupus erythematosus 
SPECT Single photon emission computed 
tomography 
TAM Tumour associated macrophage 
TCR T cell receptor 
TGF Tumour growth factor 
TLR Toll-like receptor 
TNF Tumour necrosis factor 
Treg Regulatory T cell (CD4+) 
VEGF Vascular endothelial growth factor 
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